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INTRODUCTION
1.

This civil action is brought by Attorney General G. Steven Rowe in the public

interest, arising out o f the defendants’ unfair or deceptive acts and practices in connection with
the sale of, and performance of, pharmacy and pharmacy benefit management services. By this
action, the Attorney General seeks permanent injunctive relief prohibiting the defendants from
committing unfair and deceptive acts and practices in the future, as well as restitution for persons
injured by the defendants’ unlawful actions, and other remedies provided by 5 M.R.S.A. § 207 of
the Maine Unfair Trade Practices Act (“UTPA”).
THE PARTIES
2.

This action is brought by the Attorney General on behalf o f Maine citizens,

pursuant to 5 M .R.S.A. §§207and 209, and the power vested in him under common law.
3.

Defendant, Medco Health Solutions, Inc. (“Medco”), is a Delaware Limited

Liability Corporation that conducts business nationwide, with pharmacy facilities located in 12
states. It is the corporate successor to the defendant Merck Medco Managed Care, L.L.C.

Medco Health Solutions, Inc. and Merck-Medco Managed Care L.L.C. are collectively referred
to as “Medco” . Medco provides pharmacy benefit management services to persons in Maine and
nationwide.
4.

Medco operates, or has operated, prescription drug mail order pharmacies under

the names of wholly owned subsidiaries including, but not limited to, Merck-Medco Managed
Care of California, Inc.; Defendant, Merck-Medco Rx services o f Florida No. 2, L. C. (“Tampa
II”); Defendant, Merck-Medco Rx services of Florida, L.C. (“Tampa I”); Merck-Medco Rx
services of Massachusetts, L.L.C.; Defendant, Merck-Medco Rx services ofNevada, Inc.;
Merck-Medco Rx services of New Jersey, L.L.C.; Merck-Medco Rx services of New York,
L.L.C.; Merck-Medco Rx services o f Ohio, Ltd.; Merck-Medco Rx services of Ohio No. 2, Ltd.;
Merck-Medco Rx services o f Oklahoma, L.L.C.; Merck-Medco Rx services of Pennsylvania,
L.L.C.; Merck-Medco Rx services of Pennsylvania No. 2, L.L.C.; Defendant, Merck-Medco Rx
services of Texas, L.L.C.; Merck-Medco Rx services o f Virginia, L.L.C.; and Merck-Medco Rx
services of Washington, Inc. (collectively “mail order pharmacies”). Each of Medco’s mail order
pharmacies is licensed as a pharmacy under the laws o f the state in which it is located, and is
licensed by each state to which that mail order pharmacy ships prescriptions. Each o f the mail
order pharmacies is controlled by, and are alter egos of, Medco.
5.

Systemed, L.L.C. also is a wholly owned subsidiary o f Medco. Systemed engaged

in similar or identical pharmacy benefit manager practices as Medco, except with a client focus
on smaller to medium sized businesses. For purposes o f this complaint, Systemed is the alter ego
o f Medco.
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JURISDICTION AND VENUE
6.

. This court has jurisdiction over the subject matter and defendants of this action

pursuant to 5 M.R.S.A. § 209 and 4 M.R.S.A. § 105.
FACTS
I.

M edco’s Pharmacy Benefit Manager Business
7.

Over 150 million Americans have insurance coverage which includes a pharmacy

benefit component that pays for prescription drugs, in whole or in part. W hether provided by an
employer, a health plan, a government agency, a union or another entity (the “client”), this
pharmacy benefit is typically managed by a pharmacy benefit manager (“PBM ”). The PBM is a
business which specializes in administering the pharmacy benefit in return for payment - in some
form - by the client. Medco is a PBM. According to Medco, it is the nation’s largest PBM,
based on 2002 net revenues o f more than $32 billion.
8.

A s a PBM, Medco generally performs the following tasks for its clients:
a.

Organizing a network o f retail pharmacies (“retail network”), now
numbering more than 55,000 pharmacies, that agree to fill prescriptions
for a negotiated price.

b.

Operating mail order pharmacies which sell prescription drugs, including
more than 82 million prescriptions in 2002, directly to patients.

c.

Administering the pharmacy benefit by processing and paying claims
through operation o f a proprietary computer system.

d.

Providing patients, physicians, and clients with information about the
operation o f their pharmacy benefit and cards or other methods to access
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the benefits.
e.

Providing expert advice concerning the design o f prescription drug plans
in order to provide a quality program while containing costs to the client
and the patients. Aspects o f a pharmacy benefit plan design include levels
o f co-payment by patients, limits on total amount o f drug spending
covered, use and pricing o f generic drugs, pre-authorization requirements,
and formulary decision making such as when plans should require use o f
older, cheaper drugs before paying for newer, more expensive drugs.

f.

Providing expert advice concerning the development and management o f
formularies, as described further below.

9.

Formularies .are lists o f preferred drugs for which a plan agrees to pay on behalf of

the patient, either in whole or in part. For example, “open formularies” permit payment for any
prescription drug. “Closed formularies” limit payment to specific drug - for example, only
generics, or only one drug within a so-called “therapeutic class.” “Tiered formularies” require
patients to pay lower or higher co-pays depending on whether a drug is generic, preferred brand,
or non-preferred brand.
10.

Medco maintains a Pharmacy & Therapeutics Committee (“P&T Committee”),

composed of doctors and pharmacists, to make clinical and/or medical determinations about
which drugs to include on Medco formularies.
11.

Medco represents to its clients that its “Preferred Prescription Drug Formulary”

list is reviewed by an independent P&T committee and will allow health plans to achieve quality
care as well as cost containment objectives.
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IL

M edco’s M ail O rder Pharm acy Business
12.

A t all material times, Medco provided mail order pharmacy services to clients

including state and local governmental clients, as well as Federal employee and retiree groups
and private parties.
13.

Mail order pharmacy benefits were provided through contracts between Medco

and its clients, including State Government Plans, or through sub-contracts entered into by
entities on behalf o f the clients.
14.

Medco, itself and through the mail order pharmacies, is engaged in the practice of

pharmacy and is licensed to do so under the laws o f various states in which its mail order
pharmacies are located. As a licensed pharmacy, Medco owes certain duties to the patients
whose prescriptions it receives, fills, or arranges to fill. Medco employs licensed professional
pharmacists and licensed, certified, or designated pharmacy technicians who perform or assist in
performing professional pharmacy services for patients.
15.

Medco represents to clients and to patients that it will provide the same

professional pharmacy services performed by professional pharmacists at non-mail order
pharmacies. These services, if properly performed, assure quality o f care for patients through
prevention of adverse drug interactions, verification o f drug strength and dosage regimens,
recommendation o f alternative medically appropriate drugs, and monitoring outcomes.
16.

The mail order pharmacy contracts between Medco and its clients, including State

Government Plans, require that Medco perform professional pharmacy services consistent with
state law requirements, such as drug utilization review (“DUR”) and prescription drug
counseling. Many of Medco’s client contracts provide that Medco’s compliance with applicable
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state pharmacy law is an express condition for payment for each prescription filled by a Medco
mail order pharmacy.
17.

Client contracts with Medco for mail order pharmacy services also typically

include a number o f quality assurance standards, for example, concerning accuracy rate in filling
prescriptions (e.g., less than one error in 20,000 prescriptions), and concerning standards for
prescription turnaround time (e.g., that prescriptions will be filled within an average of three days
from receipt o f the prescription).
III.

M edco’s Drug Switching Programs
A.

Medco Offers “Drug Switching” and other Formulary Compliance Programs
Purportedly to Save Clients Money.

18.

The amount o f money spent on prescription drugs by public and private health

plans and employers has risen dramatically in the past decade. One of the principal benefits
claimed by Medco when it solicits PBM clients is M edco’s ability to save clients money on
prescription drug spending.
19.

Medco represents to existing and prospective clients that several facets of its PBM

services allow Medco to save m oney for clients. Medco agrees to provide clients prescription
drugs at a contractual discount (typically a discount off so-called “AWP”, or average wholesale
price), either through its retail pharmacy network or directly through Medco’s mail order
pharmacies. Medco also promises to save money by generating manufacturer rebates and by
engaging in “formulary compliance” programs, like drug switching, as alleged further below.
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1.

20.

Medco Offers Drug Switching Programs to Generate Rebates from Drug
Manufacturers, In Order to Save Clients Money.

In addition to agreeing to provide clients prescription drugs at a percentage

discount, Medco also represents that it will save clients money by negotiating and obtaining
“rebates” from drug manufacturers. Medco represents that its ability to earn such rebates from
drug manufacturers, and thereby save clients money, is tied to the formulary established by
Medco and to M edco’s formulary compliance efforts, including its ability to switch patients from
one brand-name drug to another.
21.

Specifically, Medco represents to clients and prospective clients that if the client

agrees to use M edco’s formulary management services, Medco will generate rebates tied to
Medco’s formulary and to switching programs, and thereby save money. In its typical contract
with clients, Medco states that it will: i) receive “Formulary Rebates” as a result o f including
branded products on Medco’s formulary; as well as ii) conduct “therapeutic interchange
programs” (i.e., switch programs) for formulary drugs, which lead to cost savings. In its
solicitation of clients and in its contracts with clients, Medco represents that formulary and
switching-based rebates and savings are integral to M edco’s ability to save clients money. In
light of Medco’s cost-savings claims, many Medco clients, including state governmental clients,
participate in M edco’s formulary management programs, such as M edco’s Preferred Prescription
Formulary and its switching programs.
22.

Critical to Medco’s representation that it will save clients money by obtaining

formulary- and switching-based rebates from drug manufacturers is M edco’s claim that it will
“pass through” to clients those rebates. M edco’s agreement to pass rebates through to its clients

7

is essential because, absent that promise, rebates generated by Medco’s formulary management
or switching programs would not necessarily result in rebates and savings to the plan, which
Medco claims are the reason its switching and other formulary compliance measures.
23.

In M edco’s solicitation o f clients, promotional materials, contracts with clients,

communications with clients, and communications with patients and others carrying out its
switch programs, Medco purposely generates the overall impression that the purpose and effect
of its drug switching programs is to save client plans money on prescription drugs.
2.

24.

M edco’s Formulary Decisions and Switch Programs Often are Driven
by its Agreements to Receive Money from Drug Manufacturers.

M edco’s formulary decisions and drug switching programs - z.e., determinations

o f which drugs will be preferred on the formulary and which drugs will be targeted for brand-tobrand drug switches - turn to a large degree on Medco’s contracts with drug manufacturers. In
its capacity as mail order pharmacy, Medco contracts with these manufacturers to purchase
prescription drugs for mail order dispensing. Medco’s contracts with manufacturers typically
contain a variety o f incentives for Medco and potential payments to Medco based on Medco’s
conduct. Because Medco strikes contracts with substantially all drug manufacturers, its
incentives for selling various drugs are numerous and complex.
25.

By way o f example, many drug manufacturers pay Medco “base” or “formulary”

rebates, typically calculated by applying a flat percentage to Medco’s purchases of that
manufacturer’s drugs. But the same manufacturer contract may contain other flat percentage
rebates identified by different names (for example, “cost-effectiveness” rebates), and also may
contain more targeted rebates that are tied to specific sales or performance goals (for example,

“market share” rebates, where percentage rebate increases on a sliding scale as market share
increases).
26.

In sum, Medco receives dozens of types o f rebates from manufacturers. Some

rebates, namely “base” and “formulary” rebates, are classified as “formulary” and thus passed
through to clients who receive a portion o f formulary rebates. Many other rebates are not
classified as “formulary” rebates by Medco, and Medco therefore retains those rebates. Until
very recently, Medco typically did not disclose to its clients the magnitude o f non-formulary
rebates that were retained by Medco. On information and belief, the vast majority o f Medco
clients never learned the magnitude of Medco retained rebates. From 1997 through 2002, the
total o f Medco-retained rebates were roughly equal in magnitude to the total o f formulary
rebates, which typically were disclosed and passed through to Medco clients (in accordance with
contracts).

3.
27.

M edco’s Managed Care Pharmacists Carry Out M edco’s Drug Switches.

M edco’s mail order drug switching programs are carried out by pharmacists and

other personnel in the Managed Care departments at M edco’s mail order pharmacies. Medco
provides training, instruction, phone scripts and other form communications to all Managed Care
personnel concerning how to solicit drug switches from prescribing doctors.
28.

M edco’s Managed Care Departments' principal purpose is to switch patients’

prescriptions from a currently prescribed drug to a target drug. These drug switches sometimes
reduce costs to clients, but always promote M edco’s financial interests, sometimes without
sufficient regard to the switch’s negative impacts on client plans or patients, as alleged below.
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B.

Medco Conducted Drug Switches That Benefited Medco but Did Not Save
Clients Money, or Did Not Save Enough Money to Justify the Intervention.

29.

Notwithstanding M edco’s representations that its switch programs are designed to

save clients money and will save clients money, Medco engaged in certain drug switches that
failed to advance the purpose promoted by Medco - saving clients and patients money.
30.

On information and belief, Medco carried out switch programs that may not have

saved money because the proposed switches either favored target drugs that were more expensive
than drugs originally prescribed, or had the effect of favoring drugs without a generic equivalent
over drugs with a generic equivalent.
31.

Medco has engaged in drug switches and made formulary decisions that generated

revenue for Medco but failed to generate cost savings or other benefits for Medco’s clients.
Medco solicited and obtained agreements with drug manufacturers by which the manufacturer
would pay Medco for drug switches, formulary preferences or formulary compliance measures
favoring the manufacturer’s products, but where the manufacturer’s payments to Medco would
not be “passed through” to M edco’s clients. When Medco, pursuant to such agreements, carried
out switches and formulary decisions to generate revenue for itself without passing through
revenue to its clients, M edco’s switch programs and formulary decisions were driven by M edco’s
conflicted interest, not by cost savings for the client.
32.

Medco also engaged in switch programs and formulary decisions that favored

M edco’s former parent company, Merck, but failed to achieve costs savings to Medco’s clients.
33.

Each o f these types o f switch initiatives increased, rather than decreased,

prescription drag spending by M edco’s clients, while enriching Medco. In light o f this conduct,
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Medco, when it solicited clients and solicited client participation in M edco’s switching and
formulary initiatives, failed to disclose material information concerning its switching and
formulary programs.
C.

Medco Conducted Drug Switches that Did Not Save Clients Money Because
The Switches Shift Switch-Related Costs to Client Plans and Patients.

34.

Notwithstanding M edco’s representations that its switch programs are designed

to, and do save clients money, Medeo has engaged in certain drug switches that, on information
and belief, increased, rather than decreased, total health care costs to M edco’s client plans and to
patients.
1.

35.

Medco Drug Switches Required Clients and Patients to Pay Costs
Attributable to the Switch.

Medco conducted switches that increased overall costs even though they may have

involved a nominally lower priced target drug. These drug switches sometimes raised health care
costs to client plans and patients, contrary to M edco’s representations, by shifting switch-related
costs from Medco to its client health plans and patients. .
36.

With respect to certain drug therapies, a switch from one drug to another in the

same therapeutic class often requires one or more tests, and may require one or more doctor
visits, to monitor the new drug therapy and ensure the new drug’s efficacy. These additional
health care costs often would not have been incurred but for Medco’s proposed drug switches.
37.

By way of example, Medco engaged in several switch programs involving statin

drugs, including Mevacor and Zocor (manufactured by Merck), Lipitor (Pfizer), Pravachol
(Bristol-Myers Squibb) and Baycol (Bayer). Statins are cholesterol lowering agents prescribed to
millions of Americans to lower cholesterol levels and to help avoid heart disease.
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38.

These various statin products are in the same therapeutic class but are not

identical. To responsibly change a patient from one statin to another, the prescribing doctor often
requires the patient to undergo a fasting lipid/ cholesterol test after commencing the new drug
therapy. After analyzing the test results, the doctor should confirm the efficacy o f the dosage or
adjust it as necessary. The statin drug switch change thus may require the patient, and his or her
health plan, to incur costs associated with lab tests and/or doctor visits.
39.

In addition to statins, Medco conducted drug switch programs involving other

therapeutic classes that ultimately caused patients and health plans to incur costs related to tests
or doctor visits attributable to the drug switch.
40.

Such tests and doctor visits, resulting from M edco’s drug switch program, cost

money. Medco did not pay for these switch-related costs; the vast majority were borne instead
by both clients and patients. Costs to the patient included applicable co-payments for testing
and/or doctor visits for dosage adjustment. The client paid the balance of the costs o f testing and
doctor visits.
41.

On information and belief, with respect to certain o f Medco’s drug switches, the

switch-related costs borne by the client plans and patients exceeded costs savings attributable to a
lower price for the new drug. In those circumstances, certain of Medco’s drug switches
increased, rather than decreased, overall costs to Medco’s client plans and patients.
2.

42.

Medco Failed to Adequately Disclose, and Failed to Comply with, Its
Policy To Cover Statin Switch-Related Costs.

W ith respect to at least statin drug switches, Medco represented that it has a policy

to address switch-related costs. In communications with doctors soliciting a statin switch,
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Medco claimed that it would pay additional costs incurred due to a Medco-proposed drug switch.
In practice, Medco fails to meaningfully follow its nominal policy to cover switch-related costs
for statin switches, instead making it difficult for doctors, plans or patients to obtain
reimbursement.
43.

When Medco undertakes certain switch programs, such as statin switches, Medco

knows that its proposed switch will result in tests and/or doctor visits for which the health plan
and patient will be charged money. Nonetheless, when Medco personnel, following Medco
scripts or forms, initially solicit switches from doctors, Medco makes no mention o f switchrelated costs. Likewise, when Medco notifies the patient o f a drug switch, it makes no mention
o f switch-related costs nor M edeo’s policy to cover those costs. Medco instructs its Managed
Care pharmacists to not discuss switch-related costs unless a doctor or patient affirmatively
demands to have costs covered. M edco’s actual practice with respect to statin switch-related
costs is designed to undermine its nominal policy to cover those costs, and has the desired effect.
44.

Even when a doctor or patient objects to switch-related costs, Medco purposely

makes it difficult for either party to obtain the benefit o f Medco’s nominal policy. Medco
pharmacists refer doctors to a separate toll free number in order to process a costs request, even
though Medco could automatically process such a doctor request. As a result of Medco’s
practices, a small percentage o f switch-related costs are actually paid by Medco, even in the
statin therapeutic class.
45.

Even when Medco agrees to reimburse a patient’s switch-related costs, that

reimbursement is limited to the co-pay incurred by the patient and does not include costs paid by
the patient’s health plan, M edco’s client.
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46.

On information and belief, Medco knew that certain drug switches would require

plans and patients to incur switch-related costs that would offset savings nominally attributable
to certain drug switches. Medco also knew that, if Medco itself covered these switch-related
costs consistent with its purported policy, these switches overall would not generate revenue for
Medco. Medco nonetheless engaged in these switches so long as they were profitable for Medco,
shifting costs to M edco’s client plans and patients so as to increase, not decrease, overall costs to
the plan and patients.
47.

In its communications with clients and patients, Medco fails to disclose its actual

practices with respect to switch-related costs and fails to disclose that the vast majority of switchrelated costs are covered by plans and patients, not Medco.
3.

48.

Other Switching Costs Are Incurred by Physicians and the Health Care
System Generally.

In addition to Medco shifting switch-related costs to its client plans and patients,

M edco’s switching programs shift considerable costs to doctors and the health care system
generally. As Medco is aware from written complaints from physicians, Medco’s drug switch
solicitations demand countless hours from physicians and their staff.
49.

To responsibly evaluate most o f Medco’s drug switch proposals, a physician

should: a) review M edco’s proposed switch; b) evaluate the patient’s history (which typically
requires staff to access the patient’s file); c) evaluate whether the proposed drug therapy is
clinically suitable for the patient; d) evaluate whether side effects or drug interactions counsel
against the switch; and e) depending on the evaluation, respond to Medco by phone or facsimile.
M any physicians have received multiple switch solicitations from Medco daily, and many
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physician’s staff field calls from Medco Managed Care personnel every day.
50.

Such an expenditure of health care resources could conceivably be justified where

M edco’s switch solicitations meaningfully decrease costs to plans and patients. But to the extent
M edco’s drug switches are motivated by Medco’s own profit as much as reducing costs, the
burden on physicians constitutes another form of inappropriate cost-shifting from Medco to
others, in order to unfairly enrich Medco.
D.

M edco’s Drug Switch Solicitations Failed to Provide Full and Accurate
Information to Doctors and Patients.

51.

Medco requires its pharmacists to follow drug switching scripts prepared by

Medco, which in some ways limits the information made available to pharmacists and
prescribing doctors related to drug switches.
52.

M edco’s Managed Care pharmacists and other employees at Medco’s mail order

facilities typically solicit drug switches using the following process: A pharmacist or assistant
telephones the prescribing physician to propose a switch for one o f the doctor’s patients. This
phone call is sometimes preceded by a facsimile to the doctor’s office proposing the switch.
Once the Medco pharmacist contacts the prescribing physician or the physician’s staff (several
calls m aybe required), the pharmacist solicits physician approval for the drug switch using
M edco’s script. A doctor also may authorize a switch by completing and returning Medco’s
facsimile switch request.
53.

If a switch is authorized by the prescribing doctor, Medco generates and sends a

letter to the prescribing doctor confirming the drug switch. Medco also sends a letter to the
patient stating that a switch has been authorized. The patient letter either accompanies the new,
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switched drag prescription (for mail order prescriptions), or asks the patient to make the switch
when his or her prescription is next filled (for prescriptions filled at retail).
54.

In several steps this switch solicitation process, Medco makes misleading

statements to promote switches or fails to disclose material facts related to switches, as alleged
below.
1.

M edco’s Switch Solicitations to Physicians.

55.

M edco’s solicitation o f drug switches from doctors is misleading because:

a)

Medco represents that it is calling on behalf of the patient’s health plan but fails to
disclose M edco’s own financial incentive for the switch.

b)

Medco generates the misleading impression that the patient’s health plan has
initiated the switch request or that Medco is calling at the plan’s direction, without
disclosing that Medco itself determines when to engage in switch programs.

c)

Some Medco personnel, in order to promote a drug switch, create the false
impression that the proposed switch is required by the patient’s health plan, and
that the currently prescribed drug will not be covered by the patient’s plan.

d)

Medco represents that the proposed switch will save the patient and/or the
patient’s plan money and that M edco’s motivation behind the proposed switch is
cost containment. These representations are false or misleading with respect to
certain switches if: i) the target drug does not cost less, ii) the switch may benefit
Medco but not the plan; and/or iii) switch-related costs incurred by the plan and
patients offset any nominal price savings.
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56.

Medco’s cost containment claims are also misleading because Medco refuses to

disclose to doctors, patients, or even its own pharmacists, any actual pricing information
concerning currently prescribed and target drugs. M edco’s scripts and instructions to its
Managed Care personnel do not include information on the price of current and target drugs.
Thus, when Medco Managed Care pharmacists initiate drug switches, they have no hard
information to support cost savings - supposedly the very basis for their solicitation.
57.

Medco’s form letters to doctors confirming a switch typically restate many o f the

misleading aspects of Medco’s initial switch solicitation to doctors. These confirming letters fail
to disclose Medco’s role in the switch, Medco’s financial incentives, and material information
concerning whether the switch will actually save money for plans and patients.
2.
58.

Medco Communications with Patients.

M edco’s form letters to patients confirming a drug switch also fail to disclose

material information, in order to limit the likelihood that patients will object to or seek to reverse
the drug switch. Medco tells patients that their doctor initiated the drug switch or “has
determined” to switch drugs therapies, failing to disclose that the switch was solicited by Medco.
M edco’s letters to patients also state that the switch will save money for the patient’s plan, but
fail to disclose Medco’s financial incentives and other material information (set forth above)
concerning whether the switch will actually save money for plans and patients.
3.
59.

Medco Switched Drugs without Doctor Authorization.

On occasion, Medco also switched prescription drugs without obtaining

authorization from the prescribing doctor. Medco personnel either claimed they had obtained
physician authority when they had not, or accepted switch authorization from a member of a
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physician’s staff that Medco knew, or should have known, lacked authority to approve a switch.

IV.

M edco’s Drug Switching Programs Implicate State Pharmacy Law and Pharmacist
Ethical Standards.
60.

Medco and its pharmacists are engaged in the “practice of pharmacy” under State

law 32 M.R.S.A. § 13702(22). A non-exclusive list o f activities that qualify as being part of the
“practice of pharmacy” under state laws include: interpreting prescription orders; dispensing and
labeling o f drugs; monitoring o f drug therapy and use; conducting drug utilization reviews;
participating in drug product selection; maintaining records; and providing information on legend
drugs.
61.

Pharmacy ethics require honesty, integrity, and professionalism at all times.

Central to pharmacy ethics is recognition that the relationship between patient and pharmacist is
a covenant based on trust and that the well-being o f the patient is primary. All engaged in the
practice o f pharmacy must be dedicated to the best interests o f the patient. Pharmacy ethics
include the duty to provide unbiased information and the duty not to provide information made
biased by pecuniary interests. Business practices and work conditions that undermine that
dedication or that impair a pharmacist’s professional judgment are unethical.
62.

Because of the potential for improper conflicts of interest, and even where neither

the patient nor the plan would be harmed by the switch, pharmacy ethics require foil disclosure
o f all material facts, including cost rationality and transparency, relating to dmg switching in
order for patients and doctors to make fully informed decisions. When a physician or consumer
asks Medco about the cost or price o f a medicine, Medco and its pharmacists are obligated to
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provide that information with respect to both the drug’s cost to the plan and the patient’s co-pay.
63.

Pharmacy ethics also demand that Medco and its pharmacists monitor the

effectiveness and the effects of the drug switches proposed by Medco. Medco has an obligation
to monitor the drug switches it proposes, both generally and as to the specific patients involved.
In addition, before proposing a drug switch, Medco pharmacists are ethically obligated to form
an independent professional judgment that a proposed switch would be in the patient’s best
interest and appropriate.
64.

Drug switches, to be ethically proposed, much also be cost-effective from an

overall health-care standpoint. Thus, drug switches that shift cost-burdens to others, such as
health plans and patients, so as to effectively increase overall health care costs, are improper and
unethical.
65.

Medco has committed unfair or deceptive acts or practices through its violation o f

pharmacy ethics in at least the following ways:
a)

By failing to fully disclose to patients, plans, and physicians all o f the material
facts supporting proposed drug switches, including the nature and amount of
M edco’s financial interest, and savings to the patient and the plan, if any;

b)

By failing to monitor and track its drug switches from a health and safety
standpoint, both individually and generally;

c)

By failing to require that its pharmacists form an independent professional
judgment about the propriety of a drug switch before proposing it, and by
promoting protocols and work conditions that operate counter to this obligation;

d)

By failing to ensure that proposed drug switches are rational, not just from a cost-
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of-drug perspective, but from an overall heath-care cost perspective, especially
where additional doctor’s visits or lab tests should be anticipated;
e)

By failing to disclose adequately and pay for additional health care costs resulting
from drug switches proposed by Medco for its own economic benefit; and

f)

By failing to provide cost and price information when requested by either the
patient or the physician.
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CAUSES OF ACTION

COUNT ONE
Unfair or Deceptive Acts or Practices
in Violation of the Unfair Trade Practices Act
66.

The allegations contained in paragraphs 1 - 65 are incorporated herein by

reference.
67.

The defendants, Medco Health Solutions, Inc. and Merck-Medco Managed Care

L.L.C. (“Medco”) have violated 5 M.R.S.A. § 207 by engaging in various unfair and deceptive
acts or practices, including but not limited to the following:
a)

Although Medco represented that the purpose and effect o f M edco’s drug
switching programs were to save money for its client plans and patients, Medco
engaged in drag switching programs that increased, rather than decreased, costs to
plans and patients, including by:
i) advocating drag switches that required follow-up patient testing and doctor
visits, which caused client plans and patients to pay switch-related costs for
testing and doctor visits;
ii) advocating drag switches where the switch-related costs borne by client plans
and patients exceeded cost savings attributable to the drug switch;
iii) advocating drag switches to higher priced drags.

b)

Medco failed to adequately follow its policy for paying statin switch-related costs
like testing and doctor visits.

c)

In soliciting and obtaining drug switches, Medco sometimes made misleading
statements to doctors and patients, and failed to disclose material information
concerning the proposed drag switches, including:
i) failing to disclose material facts concerning cost containment, that the target
drag may be more expensive, M edco’s financial interest in the switch, and switchrelated costs likely to result from the switch.
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ii) failing to disclose to doctors and patients actual pricing information with
respect to the currently prescribed and target drugs.
iii) misrepresenting to doctors that Medco was calling on behalf of the patient’s
health plan, without disclosing Medco’s own incentives for the switch solicitation;
iv) misrepresenting to patients that a drug switch was initiated by the patient’s
doctor, and failing to disclose that Medco initiated the drug switch.
d)

Medco switched prescription drugs without first obtaining authorization from the
prescribing physician, and solicited and accepted purported authorization from
persons whom M edco knew, or should have known, were not authorized to
approve a drug switch.

e)

Medco carried out switch programs but failed to adequately monitor the potential
for side effects and other negative health consequences;

f)

M edco’s switching practices sometimes encouraged pharmacist conduct contrary
to pharmacy ethical rules.
RELIEF REQUESTED

WHEREFORE, the State requests that this court:
1.

Issue a permanent injunction prohibiting the defendants, Merck-Medco Managed

Care, L.L.P. and Medco Health Solutions, Inc., their agents, employees, and all other persons and
entities, corporate or otherwise, in active concert or participation with any of them, from
engaging in unfair or deceptive conduct.
2.

Order the defendants to make full and complete restitution to each person injured

by their unfair or deceptive acts or practices.
3.

Order the defendants to pay the State of Maine civil penalties, attorneys’ fees and

costs pursuant to 5 M.R.S.A. § 209.
4.

Grant such other and further relief as the Court deems equitable and proper.
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Respectfully submitted,

G. STEVEN ROWE
ATTORNEY GENERAL

Dated: April 26, 2004
LINDA J. CONTI W
Assistant Attorney General
Maine Bar No. 3638
Office o f the Attorney General
6 State House Station
Augusta, ME 04333-0006
Telephone: (207) 626-8591

ATTORNEYS FOR STATE OF MAINE
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STATE OF MAINE
KENNEBEC, SS.

SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-04

STATE OF MAINE

)
)
)

Plaintiff,

)
-v-

)

MEDCO HEALTH SOLUTIONS, INC.,
MERCK-MEDCO MANAGED CARE, L.L.C.,

CONSENTORDER

)
)
)

)
Defendants

)

_______________________________________________ )

Plaintiff, State of Maine, acting by Attorney General G. Steven Rowe, has brought this action
pursuant to the Maine Unfair Trade Practices Act, 5 M.R.S.A. §§ 207 and 209, having filed a
complaint against the Defendants, Medco Health Solutions, Inc. and Merck-Medco Managed Care,
L.L.C., and the parties having consented to the entry of this Consent Order (“Order”) for the purposes
of settlement only, without this Order constituting evidence against or any admission by any party,
and without trial of any issue of fact or law, NOW THEREFORE, upon the consent of the parties
hereto IT IS HEREBY ORDERED, ADJUDGED AND DECREED AS FOLLOWS:
I. PARTIES
1.
2.

The State of Maine is the plaintiff in this case.
Medco Health Solutions, Inc., and its corporate predecessor, Merck-Medco Managed

Care, L.L.C., together with their subsidiaries and affiliates (hereafter collectively referred to as
“Medco”) are the defendants in this case. Medco has its principal place of business at 100 Parsons
Drive, Franklin Lakes, NJ 07417. Medco is a pharmacy benefits manager, which administers
pharmacy benefits for health plans and employers, including governmental employers.

II. BACKGROUND
1.

Beginning in August 2002, the Attorneys General7reviewed Medco's drug interchange

programs, its practices regarding the disclosure and retention of rebates received from manufacturers,
disclosures of potential costs savings to patients and client plans, and issues regarding whether the
conduct of its pharmacists violated consumer protection statutes by failing to comply with
pharmaceutical ethical principles and guidelines as alleged in the Complaint (the "Covered
Conduct"). The States specifically reviewed these practices for compliance with the States’ consumer
protection statutes12*5and subsequently filed the pending Complaint.
2.

The State of Maine and Defendants captioned above have agreed to the entry of this

Consent Order of Court for Permanent Injunction and Monetary Settlement (“Order”) by this Court to
resolve all matters of dispute between them in this action.
in . FINDINGS
1.

This Court has jurisdiction of the subject matter of this case and of the parties

consenting hereto.
2.

Venue is proper as to all parties in Kennebec County Superior Court.

1 The States of Arizona, California, Connecticut, Delaware, Florida, Illinois, Iowa, Louisiana, Maine, Maryland, Nevada,
New York, North Carolina, Oregon, Texas, Vermont, and Washington and the Commonwealths of Massachusetts,
Pennsylvania, and Virginia, participated in the investigation, and shall, for purposes of this Consent Order, be referred to
as “the States” or “the Participating States.”
2 The States’ consumer protection statutes are: ARIZONA - Consumer Fraud Act, A.R.S. § 44-1521 et seq.;
CALIFORNIA - Bus. & Prof. Code §§ 17200 et seq., and 17500 et seq.; CONNECTICUT - Conn. Gen. Stat. § 42-110a et
seq.; DELAWARE - Consumer Fraud Act, 6 Del.C. Section 2511, et seq., UDTPA, 6 Del.C. Section 2531, et seq.;
FLORIDA - Deceptive and Unfair Trade Practices Act, Fla. Stat. Ch. 501.201 et seq.; ILLINOIS - Consumer Fraud and
Deceptive Business Practices Act, 815 ILCS § 505/1 et seq. (1998); IOWA - Iowa Consumer Fraud Act, Iowa Code
Section 714.16; LOUISIANA - LSA R. S. 51:1410 and LSA R. S. 51:1401, et. seq; M AINE-Unfair Trade Practices Act,
5 M.R.S.A. § 205-A, et.seq.; MARYLAND - Consumer Protection Act, Maryland Commercial Law Code Annotated §
13-101 et seq.; MASSACHUSETTS - Consumer Protection Act, M.G.L. c. 93A et seq.; NEVADA - Deceptive Trade
Practices Act, Nevada Revised Statutes 598.0903 et seq.; NEW YORK - N.Y. Gen. Bus. Law §§ 349 & 350 and
Executive Law § 63(12); NORTH CAROLINA - Unfair and Deceptive Trade Practices Act, N.C.G.S. § 75-1.1 et seq.;
OREGON - Unlawful Trade Practices Act, ORS 646.605 to 646.656; PENNSYLVANIA - Unfair Trade Practices and
Consumer Protection Law, 73 P.S. § 201-1 et seq.; TEXAS - Deceptive Trade Practices and Consumer Protection Act,
Tex. Bus. And Com. Code § 17.47., (Vernon 2002); VERMONT - Consumer Fraud Act, 9 V.S.A. § 2451 et seq.;
VIRGINIA - Virginia Consumer Protection Act, 59.1 -196 et seq.; WASHINGTON - Unfair Business
Practices/Consumer Protection Act, R.C.W. 19.86 et seq.

2

3.

Defendants have done business in each of the States through the provision of

pharmacy benefit management services to persons who are consumers in each of the States.
4.

Defendants have, by signature of their counsel hereto, waived any right to appeal,

petition for certiorari, or move to reargue or rehear this judgment and order. Entry of this Order is in
the public interest.
5.

Entry of this Order is not a finding of liability by the defendants.

IV. DEFINITIONS
Defined Terms include:
“Actual Cost Savings” shall mean, with respect to a proposed Drug Interchange, the actual
amount in dollars a Client Plan and Patient, respectively, will save in Net Drug Costs annually if a
Drug Interchange occurs at the expected dosage, assuming the Patient will use the drug for twelve
months.
“Bundled Drug” shall mean a drug for which a rebate is given only on the condition that other
drugs from the same manufacturer are included on a formulary.
“Clear & Conspicuous” shall mean a disclosure in such size, color, contrast and location, that
it is readily noticeable, readable and understandable; is presented in proximity to all information
necessary to prevent it from being misleading or deceptive, in a manner that such information is
readily noticeable, readable and understandable and not obscured in any manner; and if a print
disclosure, it appears in a type size, contrast and location sufficient for a Patient consumer or
Prescriber to read and comprehend it. A statement may not contradict or be inconsistent with any
other information with which it is presented. If a statement modifies or is necessary to prevent other
information from being misleading or deceptive, then the statement must be presented in proximity to
that information, in a maimer that is readily noticeable, readable, and understandable, and is not
obscured in any manner. A print disclosure must appear in a type size, contrast and location
3

sufficient for a Patient or Prescriber to read and comprehend it. For purposes of this Consent
Judgment, nothing in this definition shall prevent Medco from disclosing prescription, health and
safety information first.
“Client Plan” shall mean any governmental entity, employer, insurer, union or other entity
that contracts directly with Medco to provide or administer a pharmacy benefit for such plan and its
Beneficiaries.
. “Currently Prescribed Drug” shall mean a drug prescribed for a Patient that is the subject of a
Medco Drug Interchange Solicitation.
“Drug Interchange” shall mean any change from one prescription drug to another, requested
by Medco. “Drug Interchange,” however, shall not include those Drug Interchanges:
a)

initiated pursuant to a Drug Utilization Review;

b)

initiated for Patient safety reasons;

c)

required due to market unavailability of the Currently Prescribed Drug;

d)

from a brand drug to its generic or chemical equivalent, as defined by the FDA;

e)

required for coverage reasons, that is, where the Currently Prescribed Drug is
not covered by the formulary or plan applicable to the Patient.

“Drug Interchange-Related Health Care Costs” shall mean a Patient’s co-pays for tests, doctor
visits, and other health care services that are incurred in accordance with a treating physician’s
instructions, and either a) are incurred as a result of a Drug Interchange, for the purpose of assessing
the continuum of the previous therapy, for up to six months following a Drug Interchange; or b) are
incurred as a result of a Drug Interchange Solicitation, for the purpose of assessing whether to
undertake a proposed Drug Interchange. With respect to co-pays that may be incurred for purposes of
assessing whether to undertake a proposed Drug Interchange (within clause (b) above), if, following a
Drug Interchange Solicitation, a Prescriber or Patient indicates that a proposed Drug Interchange will
result in such costs being incurred, Medco in its discretion may cease to seek the proposed Drug
4

Interchange. If a Patient, because of a deductible or cap requirement, pays actual costs of tests or
doctor visits instead of co-pays, then that Patient’s Drug Interchange-Related Health Care Costs shall
be based on the co-pay (if any) that would apply upon satisfaction of the deductible or the co-pay
applicable prior to the cap being met.
“Drug Interchange Solicitation” shall mean any communication by Medco for the purpose of
requesting a Drug Interchange.
“Generic equivalent” shall mean a medication deemed chemically equivalent to a branded
drug, signified by an AB rating by the Food and Drug Administration, approval for substitution on
any state formulary, or approval for substitution by the Medco P&T Committee.
“Manufacturer Payments” shall mean any or all compensation or remuneration Medco
receives from a pharmaceutical manufacturer, including but not limited to, rebates, regardless of how
categorized, market share incentives, commissions, mail service purchase discounts, and
administrative or management fees. It also includes any fees received for sales of utilization data to a
pharmaceutical manufacturer. It does not include purchase discounts based upon invoiced purchase
terms. For purposes of Medco’s “Manufacturer Payment Reports” provided to Client Plans
hereunder, all “Manufacturer Payments” received by Medco fit into one of two categories defined
herein, namely, “Manufacturer Formulary Payments” or “Manufacturer Additional Payments.”
“Manufacturer Formulary Payments” shall mean Payments that Medco receives from a
manufacturer in return for formulary placement and/or access, or payments that are characterized as
“formulary” or “base” rebates or payments pursuant to Medco’s agreements with pharmaceutical
manufacturers.
“Manufacturer Additional Payments” shall mean all Manufacturer Payments other than
Manufacturer Formulary Payments. These payments are not provided by Medco to those Client Plans
that have contracted to receive a certain share of “formulary” rebates or payments, although certain
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Client Plans may contract to receive a certain share of all Manufacturer Payments, including both
“Formulary” and “Additional” Payments.
“Medco” shall mean Medco Health Solutions, Inc., Merck-Medco Managed Care, L.L.C.,
their subsidiaries including all state licensed pharmacy subsidiaries and affiliated companies, their
corporate predecessors and successors, and their agents and employees, including pharmacists
directly employed by Medco.
“Medco Total Product Revenue” shall mean Medco’s net revenue which consists principally
of sales of prescription drugs to clients, either through Medco's network of contractually affiliated
retail pharmacies or through Medco's mail order pharmacies. Where Medco acts as a principal in
accordance with generally accepted accounting principles, which is the case in the majority of
Medco’s client contracts, revenues are recognized at the prescription price negotiated with clients, as
well as the associated administrative fees.
“Minimum Cost Savings” shall mean the minimum amount in dollars a Client Plan and
Patient, respectively, will save in their costs annually if a Drug Interchange occurred at the expected
dosage.
“Net Drug Cost” shall mean the price Medco charges a Client Plan and/or Patient for a
prescription drug whether that drug is delivered through a retail pharmacy or mail order. The Net
Drug Cost may take into account all discounts, rebates, credits or other payments that lower the cost
of the drug, to the extent such payments are provided to the Client Plan. Net Drug Cost may be
reduced by Manufacturer Payments to the extent those payments are provided to the Client Plan, but
shall not be reduced by Manufacturer Payments that are paid to and retained by Medco.
“Patient” shall mean a person whose prescription drug benefit is administered by Medco.
“P&T Committee” shall mean the Pharmacy & Therapeutics Committee maintained by
Medco, comprised of at least seven members, all of whom shall be physicians, pharmacists, or other
health care professionals, and a majority of whom are actively practicing and who are not employed
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by Medco, responsible for determining Medco’s standard formularies, the clinical appropriateness for
Medco concerning Medco’s Drug Interchange programs, developing and maintaining clinical criteria
used as a basis for Medco’s standard coverage management program, and other responsibilities
pertaining to the clinical components of programs and services designed to effect drug utilization.
“Prescriber” means a physician, dentist, physician’s assistant, optometrist or other health care
professional authorized by law to write prescriptions for prescription drugs.
“Proposed Drug” shall mean the drug or drugs that Medco, in its Drug Interchange
Solicitation, proposes to substitute for a Currently Prescribed Drug.

V. INJUNCTION
A,

Restrictions on Drug Interchanges and Required Disclosure of Pricing
Information

Unless otherwise specifically directed by a Client Plan with respect to a proposed Drug
Interchange, Medco shall not do any of the following:
1.

Make any Drug Interchange Solicitation where the Net Drug Cost of the Proposed

Drug exceeds that o f the Currently Prescribed Drug. Medco shall allocate Bundled Drug rebates and
discounts to the Net Drug Cost of each drug in the manner agreed to between Medco and the Client
Plan.
2.

Make any Drug Interchange Solicitation where the Currently Prescribed Drug has

generic equivalents and the Proposed Drug has no generic equivalents, unless the Proposed Drug has
a lower Net Drug Cost than all generic equivalents of the Currently Prescribed Drug.
3.

Make any Drug Interchange Solicitation where the patent protection for the Currently

Prescribed Drug is scheduled to expire within six months of the Drug Interchange Solicitation, or
where the effect of the proposed Drug Interchange reasonably is to avoid substitution for, or generic
competition against, the Currently Prescribed Drug (excepting Drug Interchanges with the effect of
decreasing Net Drug Costs).
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4.

Make any Drug Interchange that fails to disclose to Prescribers and Patients, Clearly

and Conspicuously, Minimum Cost Savings, or Actual Cost Savings, as well as the difference, if any,
in co-payments to be made by the Patient (or absence of effect on co-payments, if such is the case).
When making these disclosures, Medco may reasonably rely on information provided by the Client
Plan with respect to eligibility and co-payments, irrespective of deductibles and caps.
5.

Make any Drug Interchange Solicitation to a Patient who, within two years preceding

the solicitation, and with respect to the same therapeutic class involved in the proposed Drug
Interchange, has either a) interchanged his or her drug following a Drug interchange Solicitation from
Medco or b) interchanged his or her drug following a Medco Drug Interchange Solicitation but had
the Interchange reversed, unless all of the Proposed Drugs in the current Drug Interchange
Solicitation were not among the Proposed Drugs in the prior Drug Interchange Solicitation.
B.

Medico’s Payment of Drug Interchange-Related Health Care Costs

1.

Medco shall pay all out-of-pocket costs for Drug Interchange-Related Health Care

Costs incurred by a Patient by reimbursing the Patient for such costs, within thirty days of receipt of a
claims form for such costs.
2.

Medco shall enact and follow a procedure for reimbursing Patients such out-of-pocket

costs, by which Medco shall, without limitation, (a) permit Patients, Prescribers or Treating
Physicians to request such reimbursement, by phone or in writing, and (b) upon such request, provide
a single-page claim form (with instructions) to request reimbursement. For reimbursement requests
initiated by Patients (not Prescribers or Treating Physicians), Medco may (but need not) require that
the Patient’s reimbursement claim provide information showing that Interchange-Related Health Care
Costs were incurred, which requirement may be satisfied by a Physician or Prescriber’s notation at a
designated place on the claim form, or by providing a. Physician’s written order, or other evidence
showing payment of costs (e.g., co-pays for tests or doctor visits) incurred as a result of a Drug

Interchange. Medco shall not directly or indirectly prevent or discourage Patients or Doctors from
requesting or receiving reimbursement for Drug Interchange-Related Health Care Costs.
3.

Medco’s written communications to both Prescribers and Patients concerning Drug

Interchanges, as set forth below, shall Clearly and Conspicuously disclose Medco’s policy, consistent
with this section, with respect to Drug Interchange-Related Health Care Costs. Medco’s telephone
communications with Prescribers and Patients concerning Drug Interchanges, as set forth below, shall
communicate the existence of Medco’s policies with respect to Drug Interchange-Related Health Care
Costs. In its communications with Prescribers, Patients and Client Plans, Medco shall not
misrepresent, directly or indirectly, its policy with respect to Drug Interchange-Related Health Care
Costs.
4.

Should Drug Interchange-Related Health Care Costs paid to a Patient with respect to

any particular Interchange exceed $500.00, Medco, while complying with the timely reimbursement
requirement set forth in B. 1., above, may, in its sole discretion, choose to have a third party chosen by
Medco to review the costs paid. If a determination is made that the costs were not related to an
Interchange, nothing herein shall prevent Medco from pursuing any legal remedies Medco may have
against the Patient and any other party involved.
C.

Medco’s Drug Interchange Solicitation Process and Disclosure of Pricing
Information

1.

Drug Interchange Solicitation to Prescribers.

Medco shall not interchange (or obtain an interchange promise for) the prescription drug of
any Patient without first obtaining express verifiable authorization from the Prescriber of the
Currently Prescribed Drug. All Medco Drug Interchange Solicitations to a Prescriber shall:
a)

identify the name and title of the person making the Drug Interchange
Solicitation;

b)

state that Medco is soliciting a Drug Interchange;
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c)

identify the Minimum Cost Savings or Actual Cost Savings to be achieved by
interchanging to the Proposed Drug from the Currently Prescribed Drug;

d)

describe under what circumstances the Currently Prescribed Drug will continue
to be covered by the Client Plan, if such is the case;

e)

describe the difference in co-pay, if any, or the absence of effect on co-pay, if
such is the case;

f)

if Medco receives Manufacturer Payments from a drug manufacturer as a result
of the Proposed Drug Interchange or the Interchange Solicitation that is not
reflected in Net Drug Cost because it is compensation that does not inure to
Medco’s Client Plan, Medco shall disclose that it receives such compensation
or potential compensation;

g)

Disclose the existence of Medco’s policy with respect to Drug InterchangeRelated Health Care Costs outlined in Paragraph V.B. If the Drug Interchange
Solicitation is written, this disclosure shall be clear and conspicuous and direct
the Prescriber to the written communication (Confirmation to Prescribes,
provided below) for details. If the Drug Interchange Solicitation is by
telephone, Medco may disclose its policy by directing the Prescriber to the
written communication for details;

h)

Disclose any material differences, as determined by the Medco P&T
Committee, between the Currently Prescribed Drug and the Proposed Drug
with respect to side effects or potential effects on patient health and safety.

2.

Authorization and Written Confirmation to Prescribes for Drug Interchanges for

home delivery or promises for Drug Interchanges obtained at retail.
(a).

Medco shall not Interchange a Patient’s drug absent express verifiable authorization
from the Prescriber, as communicated (i) directly by the Prescriber (in writing or
10

verbally) or (ii) by a person who affirms (in writing or verbally) that the Interchange
has been authorized by the Prescriber. If such authorization is by a person other than
the Prescriber and verbal, Medco shall request that person’s name and title or position.
(b).

Medco shall maintain records memorializing, with respect to each Drug Interchange,
how express verifiable authorization was obtained, including the name of the person
providing express verifiable authorization of the Drug Interchange; whether the
authorization was written or verbal; and, if verbal and by a person other than the
Prescriber, that person’s title or position, if provided.

(c).

Upon such express verifiable authorization of a Drug Interchange, Medco shall send a
written communication to the Prescriber confirming the Interchange. If the
Solicitation (containing the requirements above) was not in writing, then the written
confirmation shall include the information required in Section V .C .l. Regardless
whether the Interchange Solicitation was in writing, the written confirmation shall:

i)

identify the Minimum Cost Savings or Actual Cost Savings resulting from the
interchange;

ii)

Clearly and Conspicuously disclose Medco’s policy with respect to Drug InterchangeRelated Health Care Costs, in accordance with Section V.B.; and

iii)

provide a toll free telephone number for the Prescriber.

3.

Interchange Confirmation to Patient.

With respect to Medco home delivery prescriptions, within 24 hours of express verifiable
authorization of a Drug Interchange by the Prescriber or dispensing the Proposed Drug, whichever is
earlier, Medco shall send to the Patient a written communication (“Written Patient Drug Interchange
Notice,”) and make a telephonic communication (“Telephonic Patient Drug Interchange Notice”)
advising the Patient of the Prescriber’s approval of the Drug Interchange. Following express
verifiable authorization of a Prescriber’s approval of a Drug Interchange for a non-home delivery
11

prescription, Medco shall send the Patient a Written Patient Drug Interchange Notice. The Written
Patient Drug Interchange Notice shall Clearly and Conspicuously:
a)

state that Medco requested a Drug Interchange by contacting the Patient’s Prescriber;

b)

state that, following Medco’s Interchange Solicitation, the Prescriber approved the
Drug Interchange;

c)

not represent that the Prescriber initiated the Interchange;

d)

identify the Proposed Drug and the Currently Prescribed Drug;

e)

identify the Minimum Cost Savings or Actual Cost Savings;

f)

describe under what circumstances the Currently Prescribed Drug will continue to be
covered by the Client Plan, if such is the case;

g)

describe the difference in co-pay, if any, or the absence of effect on co-pay, if such is
the case;

h)

if Medco receives compensation from a drug manufacturer as a result of the Proposed
Drug Interchange or the Drug Interchange Solicitation that is not reflected in the Net
Drug Cost because it is compensation that does not inure to Medco’s Client Plan,
Medco shall disclose the fact of such compensation or potential compensation;

i)

disclose Medco’s policy with respect to Drug Interchange-Related Health Care Costs,
in accordance with Section B; and

j)

advise the Patient that he or she may decline the Drug Interchange in which case the
Patient will receive the Currently Prescribed Drug, if the currently Prescribed Drug
remains on the Client Plan’s formulary and the Patient is willing to pay any difference
in Co-Pay.

The Telephonic Patient Interchange Notice made for Medco home delivery Drug Interchanges
shall:
a)

state that Medco requested a Drug Interchange by contacting the Patient’s Prescriber;
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b)

state that, following Medco’s Interchange Solicitation, the Prescriber approved the
Drag Interchange;

c)

not represent that the Prescriber initiated the interchange;

d)

advise the Patient that further written information about the Drag Interchange will
arrive in the mail and give a toll-free telephone number so that the Patient may speak'
to a customer service representative about the Interchange.

4.

Rejected Interchanges.

Unless a Currently Prescribed Drug is no longer on the Client Plan’s formulary or the Patient
is unwilling to pay any higher applicable Co-Pay or other costs, Medco shall cancel and reverse the
Drug Interchange upon written or verbal instructions from a Prescriber or Patient. Medco shall
maintain a toll free telephone number(s) during business hours (currently 8:00 a.m. to 8:00 p.m.
Eastern, but in any event at least eight hours a day, Monday through Friday) to field telephone calls
from Patients and Prescribes in response to Medco’s interchange confirmations, and the customer
service standards (e.g., waiting time) for those telephone numbers shall be equivalent to Medco’s
other customer service standards. Upon cancellation, if Medco has not yet dispensed the Proposed
Drug, Medco, upon approval o f the Prescriber, shall dispense the Currently Prescribed Drag. If
Medco has already dispensed the Proposed Drug, Medco shall obtain a prescription for, and dispense
the Currently Prescribed Drug, and Medco shall charge the Patient only one co-pay and shipping and
handling fees (so that a proposed but reversed Interchange will not increase Patient costs beyond the
costs had Medco dispensed the Currently Prescribed Drug). Unless otherwise provided by contract
with a Client Plan, Medco shall also bear the expense of shipping the Proposed Drug back to Medco
(either by offset or by reversing and crediting the initial co-pay). Medco will provide notice to Client
Plan that Client Plans may request information regarding the costs to it resulting from a Patient’s
rejection of a Proposed Drug Interchange. In the event a Patient will exhaust his or her supply o f the
Currently Prescribed Drug before a replacement shipment will arrive to the Patient, Medco shall
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arrange for dispensing of an appropriate quantity of replacement medications at a participating Medco
network pharmacy at no additional cost to the Patient. Further, in the event that a Patient reverses an
Interchange and Medco is unable to obtain approval from the Prescriber (or a physician covering for
Prescriber) for the Currently Prescribed Drug, Medco shall take reasonable steps to provide either the
Currently Prescribed Drug or the Proposed Drug before the Patient exhausts his or her existing
supply.
5.

P & T Committee representations in all Interchange Communications.

With respect to all Drug Interchange Solicitations and communications related to Drug
Interchanges, Medco shall not misrepresent the role of Medco’s P&T Committee in initiating,
reviewing, approving or endorsing a Proposed Drug Interchange or Interchange Solicitation. If
Medco mentions the P&T Committee in any Interchange Solicitation or communication related to
Drug Interchanges, Medco shall Clearly and Conspicuously:
a)

disclose the role of Medco’s P&T Committee in Medco’s Interchange proposal;

b)

disclose that the Interchange being proposed by Medco was not initiated by the P&T
Committee and not initiated due to medical care considerations;

c)

disclose that the P&T Committee did not consider cost issues, if such is the case.

6.

With respect to the operation of the P&T Committee, Medco shall provide to each plan

(at the Plan’s expense, unless the Client Plan contract otherwise provides), upon request:
a)

copies of all information provided to the P&T Committee;

b)

copies of all minutes of the P&T Committee;
i)

Minutes shall include the list of attendees at the meeting, the record of all votes
to approve or disapprove a drug for the formulary, or therapeutic interchange
or other action undertaken by the committee, a summary of any discussion of
material differences between a Currently Prescribed Drug and a Proposed Drug
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with respect to side effects or potential effects on patient health and safety, and
a summary of all discussions on each agenda point.
In addition, regardless whether provided by contract, Medco shall advise each plan that it may
send a representative, at the plan’s expense, to attend any P&T Committee meeting, subject to
reasonable space limitations, which may restrict the number of such observers at each meeting to five
plans.
7.

In the event Medco’s P&T Committee approves a Drug Interchange with conditions,

Medco shall provide a complete description of such conditions to the Prescriber at the time of the
Interchange Solicitation.
D.
1.

Medco Monitoring of Interchange Health Effects
Medco shall monitor the effects of Drug Interchanges requested by Medco upon the

health of Patients, and shall report to Medco’s P&T Committee, not less than quarterly, the results of
such monitoring. Such monitoring shall include, without limitation, a system designed to a) identify
Patient and Prescriber communications with Medco that concern the efficacy or health effects o f a
Drug Interchange, and b) capture information from such communications in a manner that Medco can
collect, and generate reports on, Patient and Prescriber communications concerning Drug
Interchanges. Medco shall report the results of such monitoring to Medco’s P&T Committee, not less
than quarterly, and the P&T Committee shall reasonably consider the results of Medco’s monitoring.
E.

Medco’s Disclosure to Client Plans of Compensation From Drug Manufacturers

1.

Quarterly and Annual Disclosures. With respect to each Client Plan that has

contracted to receive (directly or by credit) any Manufacturer Payments from Medco, for each Medco
Fiscal Year during which the Client Plan receives any such Manufacturer Payments, Medco shall
provide those Client Plans, for each Medco fiscal quarter and year, a Manufacturer Payments Report.
Medco’s Manufacturer Payment Reports shall identify, for the reported fiscal quarter or year (the
“reporting period”), the information set forth below at (a) through (e). If the precise reported figure is
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not known by Medco at the time of its report, Medco shall provide its current best estimate of the
reported information, provided that, with respect to each report, should the reported information
subsequently need revision in accordance with generally accepted accounting principles, Medco will
provide an update to the reported information to reflect that revision.
a)

the dollar amount o f Medco Total Product Revenue (as defined) for the reporting
period, with respect to Medco’s entire client base, together with:

b)

the dollar amount of total drug expenditures for each Client Plan;

c)

the dollar amount o f all Manufacturer Payments earned by Medco for the reporting
period;

d)

the percentage o f all Manufacturer Payments earned by Medco for the reporting period
that were Manufacturer Formulary Payments; and

e)

the percentage o f all Manufacturer Payments received by Medco during the reporting
period that were Manufacturer Additional Payments.

Medco’s Manufacturer Payment Reports shall present the above information in a Clear and
Conspicuous manner that serves to inform Client Plans of all Manufacturer Payments earned by
Medco, including, for instance, those Client Plans that share only in Manufacturer Formulary
Payments but not Manufacturer Additional Payments.
2.

Disclosure at Contracting Stage. Medco shall disclose to each Client Plan or

prospective Client Plan, in advance o f executing an agreement (whether an initial or renewal contract)
with such Client Plan:
a)

that Medco will solicit and receive Manufacturer Payments and that Medco may pass
through those payments to Client Plans or may retain those payments for itself,
depending on contract terms.

b)

the information set forth in Medco’s Manufacturer Payment Report pursuant to
Section E. 1 (a), (c), (d) and (e) above, concerning the most recent Medco fiscal year
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for which such information is publicly available, at the time of the communication
under this section.
c)

that Medco will report, quarterly and annually, on Manufacturer Payments, consistent
with Section E(l) above.

F.

Pharmaceutical Ethics

1.

Medco shall adopt the code of ethics of the American Pharmacists Association for its

employed pharmacists. Medco accepts the APhA Principles of Practice for Pharmaceutical Care as a
framework for ongoing evolution of its pharmacy practice. Medco will provide these documents to
all staff pharmacists with any necessary explanations to make clear to staff pharmacists that Medco is
striving to achieve the objectives established by the profession.
2.

Medco shall make available to its employed pharmacists, Client Plans and Patients

copies (which may be in electronic form or available on a web site) of such codes of ethics or
professional standards.
3.

Medco shall require its pharmacists to comply with all state law requirements

governing pharmacists.
4.

Medco shall permit its pharmacists to give good faith, professional opinions.

5.

Medco shall require that its pharmacists form an independent professional judgment

that a Drug Interchange would be in a Patient’s best interest before soliciting a Drug Interchange.
G.

Additional Price Transparency Remedies

1.

Medco shall not refuse to respond to Request for Proposal or Request for Bid from a

plan on the grounds that the proposal does not use AWP or prohibits the use of AWP in pricing terms
and Medco, if so asked, shall communicate to each plan that pricing methods other than use of AWP
are available.
2.

Medco shall not describe relative prices of drugs by use of symbols or other indirect

means without disclosing a price range those symbols represent.
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VI.

REIMBURSEMENT AND CY PRES PAYMENT

A. Reimbursement.
1.

Medco shall pay up to $2.5 million to reimburse “Affected Consumers,” as defined

below, up to $25.00 each for out-of-pocket expenses incurred as a result of a “Statin Drug
Interchange,” using the notification and claims process described in Section VI.A. 1 & 2. For
purposes of this section, a “Statin Drug Interchange” means a Patient’s Drug Interchange, from one
already dispensed branded drug to another branded drug within the HMG-CoA Reductase Inhibitors
therapeutic class, from January 1, 2000 through the Effective Date. “Affected Consumers” means
those persons who (i) following a Statin Drug Interchange, paid co-pays for tests, doctor visits or
other health care services incurred as a result of the Statin Drug Interchange, (ii) have not received
reimbursement from Medco for those out-of-pocket expenses, and (iii) currently reside in a
Participating State or resided in a Participating State at the time of the Statin Drug Interchange at
issue.
2.

Medco, or its designee, shall identify and pay Affected Consumers using the following

notification and claims process, the costs of which shall be borne by Medco:
a.

Using its Patient records and records related to Drug Interchanges, Medco shall
identify all Patients who had a Statin Drug Interchange, including statin prescriptions
filled by a Medco home delivery (mail order) pharmacy or at retail following a “retail
promise” letter from Medco (collectively, “Potential Affected Consumers”). Medco
shall make reasonable efforts to identify the current address for each Potential
Affected Consumer, using its current Patient records and skip-tracing.

b.

Medco shall mail to each Potential Affected Consumer a “Reimbursement Notice and
Claim Form,” in a form (or forms) approved by the participating Attorneys General.
The Reimbursement Notice shall, clearly and conspicuously, (i) advise Potential
Affected Consumers that Medco reached a settlement with the participating Attorneys
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General, and that Medco will reimburse Affected Consumers up to $25.00 for
interchange-related expenses, (ii) explain how Affected Consumers may obtain
reimbursement, and (iii) explain that Affected Consumers must submit all claims to
Medco within six months of the Affected Consumer’s receipt of the notice and claims
form.
c.

The Claim Form, which shall be coupled with the Reimbursement Notice, may request
that the Potential Affected Consumer: i) generally describe any costs incurred as a
result of a Statin Drug Interchange; and ii) attest, under penalty of perjury, that the
information provided on the claim form is true and accurate. The Claim Form also
will advise the Potential Affected Consumer that acceptance of reimbursement
pursuant to the claims process will reduce, by the reimbursement amount, any
recovery by any other means, of out-of-pocket costs attributable to co-pays for tests,
doctor visits or other health care services incurred as a result of the Statin Dmg
Interchange. A pre-paid envelope shall accompany the Reimbursement Notice and
Claim Form. The Claim Form also shall provide a toll-free number for Potential
Affected Consumers to call should they have questions.

d.

Medco shall mail all notices as soon as practicable following the Effective Date, but in
any event within four months of the Effective Date. Medco then shall accept claims
for seven months after the last mailing of notice and claim forms (“the time period”).
After expiration of the time period, Medco shall make reimbursement of $25.00 to
each Affected Consumer who submits a completed claim form and attests that he or
she incurred out-of-pocket expenses following a Statin Drug Interchange (a “qualified
claim”). In the event that, after expiration of the time period, Medco has received
qualified claims in an amount that exceeds $2.5 million based upon a $25.00 payment
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(i.e., more than 100,000 qualified claims), then payments to Affected Consumers shall
be prorated by dividing the $2.5 million by the number of qualified claims received.
e.

Following completion of the above notification and claims process, and in any event
not more than 12 months after the Effective Date, Medco shall certify to the
participating Attorneys General that it has complied with this reimbursement section
and provide a report identifying, without limitation: i) the number of Reimbursement
and Claims Forms mailed to Potentially Affected Consumers, ii) the number of phone
calls received concerning the notice and claims process, iii) the number of claims
forms submitted, iv) the number of qualified claims submitted, v) the total amount in
reimbursement paid by Medco to Affected Consumers, and vi) the costs of
administration of this reimbursement program.

B.

Cv Pres Payment.

1.

Medco shall pay the participating State Attorneys General $20,200,000, as described

further in this section VLB, to be apportioned among the participating states proportionally based
upon population, with a minimum per state distribution, as agreed by the participating states. Each
state’s proportional share of the $20.2 million shall be reflected in a schedule provided to Medco in
advance of the Effective Date (the “State Schedule”).
2.

Within a reasonable time after the Effective Date, but not to exceed 90 days after the

Effective Date, each participating State shall elect whether to receive its proportional share as a
monetary payment or, in whole or in part, as pharmaceuticals as described further in VLB.5 & 6,
below, and shall provide Medco written notice of its election. Each State electing to receive a
monetary payment shall include, in its written notice of election, payment instructions (i.e., to whom
payment should be directed).

Each State making a partial election (i.e., choosing both monetary

payment and pharmaceuticals), shall express the elected monetary payment in dollars, indicating that
any balance of that state’s distribution be apportioned to pharmaceuticals.
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3.

Within 14 days of its receipt of such written notice of a State’s election, Medco shall

pay to the State, by check and consistent with the State’s reasonable payment instructions, that
portion of the State’s proportional share that, consistent with the State’s election, is to be paid in cash
(the “Monetary Portion”). Each state’s Monetary Portion shall not exceed the State’s proportional
share of the $20.2 million set forth on the State Schedule. Medco need not pay a State’s Monetary
Portion until: a) Medco has received the State’s written notice of election, described above, and b) the
State has entered a Consent Order in its state court in substantively the same form as this Consent
Order.
4.

States that receive a monetary payment shall make a cy pres distribution of these

funds, pursuant to a state-specific Cy Pres Distribution Plan, to a political subdivision(s) thereof or to
a state agency or program, a non-profit corporation(s) and/or a charitable organization(s), at the sole
discretion of the Attorney General of each Respective State, with the express condition that the funds
be used to benefit low income, disabled, or elderly consumers of prescription medications, to promote
lower drug costs for residents of that State, to educate consumers concerning the cost differences
among medications, or to fund other programs reasonably targeted to benefit a substantial number of
persons affected by the Covered Conduct that is the subject of this Consent Order.
5.

As an alternative to monetary payment of their respective proportional share of this cy

pres payment, participating states may elect (as described in B.2, above) to receive their respective
payment under this section, in whole or in part, in the form of pharmaceuticals to be provided by
Medco, pursuant to section B.6, immediately below. Each State electing to receive pharmaceuticals
via the pre-paid generic card described in section B.6(b) below, shall be entitled to receive
pharmaceuticals distributed under section B.6(b), valued as described below, in an amount equal to its
proportional share of the $20.2 million cy pres payment plus 25 per cent (the “State pharmaceutical
amount”), such that the value of this alternative cy pres distribution would increase to $25.25 million
in the event all Participating States elected to receive pharmaceuticals via the pre-paid generic card.
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6.

Distribution of pharmaceuticals. Medco shall provide pharmaceuticals, up to the State

pharmaceutical amount, to each State electing to receive pharmaceuticals (“electing State”), in either
or both of two ways, as chosen by the electing State:
a)

Shipment of pharmaceuticals to designated facilities: Medco shall provide
pharmaceuticals to facilities designated by the electing State Attorney General or his
or her lawful designee (“designated facilities”), by paying for drug purchases by
designated facilities up to each designated facility’s allotted pharmaceutical amount, as
described herein. A designated facility may be a health clinic, hospital, pharmacy,
charitable organization, governmental agency or governmental entity, and must
dispense medications in a manner that complies with all applicable state and/or federal
laws. The electing State Attorney General shall designate the facilities to receive
pharmaceuticals and, for each designated facility, the portion (in dollars) of the State
pharmaceutical amount allocated to the facility, up to the total State pharmaceutical
amount. Upon such designation, a designated facility, after purchasing
pharmaceuticals in its normal course of business, may either: (i) forward to Medco
unpaid invoices for pharmaceutical purchases by the designated facility, which Medco
shall pay, up to the designated facility’s allotted pharmaceutical amount, within a
reasonable time period, not to exceed thirty days after Medco’s receipt; or (ii) forward
to Medco paid invoices for pharmaceutical purchases which Medco shall pay, up to
the designate facility’s allotted pharmaceutical amount, within a reasonable time
period, not to exceed thirty days after Medco’s receipt. Medco may require that all
requests for payment from designated facilities pursuant to this subsection be received
by Medco within two years of the Effective Date. In the event that invoices forwarded
to Medco reflect non-public, proprietary pricing information of a designated facility,
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the designated facility may take reasonable steps to avoid disclosure of the proprietary
pricing information.
b)

Pre-paid generic drugs card: Medco shall provide pre-paid generic drug cards (“drug
cards”) to the electing State Attorney General or its lawful designee, for distribution, at
the discretion of the Attorney General or its designee, to persons or organizations in
the electing State in order to provide generic pharmaceuticals, at no cost, to persons in
need, either directly or through organizations. The drug cards shall have a
predetermined value (e.g., $250.00) agreed to by the electing State and Medco
(between $150.00 and $400.00, available only in $50.00 increments). Upon
distribution of the drug cards, card holders may use the drug card to pay for generic
drug prescriptions ordered and filled through Medco’s home delivery pharmacies. To
facilitate distribution of drugs paid for by the drug card, Medco may require the card
holder to complete a standard enrollment form for its home delivery pharmacies. With
respect to such enrollment, and with respect to prescription dispensing practices,
protection of personal information, pharmacist consultation and customer service, card
holders shall receive Medco’s standard terms and pharmacy services provided to other
Patients. Beyond providing its standard pharmacy services and customer service to
card holders in connection with filling prescriptions for card holders, Medco shall not
market other goods or services to card holders, and shall not sell or provide card
holders’ personal information to any other entity. For purposes of exhausting a drug
card’s predetermined value, the value of drugs dispensed under each drag card shall be
the lower of (i) Medco’s Medicare MAC or (ii) HCFA MAC minus ten percent (10%), at the time of dispensing. Medco may limit generic dispensing pursuant to this
subsection to prescriptions received by Medco within (i) eighteen months of each card
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holder’s initial enrollment (i.e., first prescription order), or (ii) two years of the
Effective Date, whichever is earlier.
Regardless whether an electing State chooses pharmaceutical distribution via payments to designated
facilities or generic drug cards, or both, each electing State shall designate, not later than 30 days after
the Effective Date, a person to serve as the electing State’s liaison with Medco for the purpose of
effecting the distribution of pharmaceuticals hereunder (including, for example, notifying Medco of
the electing State’s choice of distribution, designation of facilities, or determination of drug card
values). Not later than 30 days after the Effective Date, Medco shall designate a person to serve as
liaison to each electing State to effect such distribution and compliance with this program.
VII.
A.

PAYMENT OF FEES AND COSTS TO THE STATES

Fees and Costs to the States. On or before the Effective Date of this Order, Medco

shall pay $6.6 million to the participating State Attorneys General, to be distributed among those
participating states as agreed by the Attorneys General, for attorney’s fees and investigative costs,
consumer education, litigation, public protection, consumer protection purposes or local consumer aid
funds or any other purpose permitted by state law at the sole discretion of each state’s Attorney
General.3 Medco shall pay this amount by check to the Office of the Pennsylvania Attorney General.
The Pennsylvania Attorney General shall hold that payment in trust and, as soon as practicable but
not later than six months after receipt, shall distribute the payment among the participating states
pursuant to the participating states’ agreement, provided, however, that, prior to receiving its allotted
distribution hereunder, a State has entered in its State a Consent Order in substantively the same form
as this Consent Order.

3 Money paid to the Maine Attorney General pursuant to this Section VII A. shall be allocated by the Attorney General to
the reimbursement of investigative costs and attorney fees pursuant to 5 M.R.S.A. § 209.
24

VIII. GENERAL PROVISIONS
1.

Scope of Consent Order. The injunctive provisions of this Consent Order are entered

into pursuant to the Maine Unfair Trade Practices Act, § 209 and M.R. Civ.P. 65 and are applicable to
Medco, its officers, agents, employees, and attorneys, and all those persons or entities in active
concert or participation with them who receive actual notice of this Order by personal service or
otherwise, whether acting directly or through any entity, corporation, subsidiary, division, or other
device.
2.

Release of Claims. By its execution hereof, the State releases Medco and all of its

subsidiaries, affiliates, assigns, corporate predecessors and successors (“Releasees”) from all civil
claims, causes of action, damages, restitution, fines, costs and penalties on behalf of the State, which
the State asserted or could have asserted from January 1, 1995, through the date the parties execute
this Consent Order, under the above-cited consumer protection statutes and any antitrust or unfair
competition laws, relating to or based upon the Covered Conduct which is the subject of this Consent
Order.
The State agrees that it shall not proceed with or institute any civil action or proceeding, either
individually or collectively, based upon these statutes, laws and regulations against the Releasees,
including but not limited to an action or proceeding seeking restitution, injunctive relief, fmes,
penalties, attorneys fees or costs for any conduct undertaken or omissions prior to the date the parties
execute this Consent Order which relates to the Covered Conduct. The State shall also not initiate
any claim in the nature of a class action with respect to any Covered Conduct from January 1,1995,
through the date the parties execute this Consent Order. Medco may plead this Order as a full and
complete defense to any claim, whether class, individual or otherwise in nature, released hereunder
that may be instituted, prosecuted, or attempted by any Settling State with respect to the Covered
Conduct.
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Notwithstanding the foregoing, the State does not release any claim arising under statutes,
laws or regulations other than those identified herein and in section 11(1) above and arising out of the
Covered Conduct which is the subject matter of this Consent Order. Claims excluded from the
State’s release include, but are not limited to, claims relating to Best Price, Average Wholesale Price
or Wholesale Acquisition Cost reporting practices or Medicaid fraud or Abuse. In addition, the State
does not release any claim, right or cause of action that could be brought by any consumer or brought
by any person or entity other than the State. Moreover, the State may institute an action or
proceeding to enforce the terms and provisions of this Consent Order or take action based on future
conduct by the Releasees.
3.

Preservation of Law Enforcement Action. Nothing herein precludes the State from

enforcing the provisions of this Consent Order, or from pursuing any law enforcement action with
respect to the acts or practices of Medco not covered by this Consent Order or any acts or practices of
Medco conducted after the Effective Date of this Consent Order.
4.

Compliance with and Application of State Law. Nothing herein relieves Medco

of its duty to comply with applicable laws of the State nor constitutes authorization by the State for
Medco to engage in acts and practices prohibited by such laws. This Consent Order shall be
governed by the laws of each o f the respective States, with respect to Medco’s conduct in each o f the
States.
5.

Non-Approval of Conduct. Nothing herein constitutes approval by the State of

Medco’s drug interchange program or other business practices. Medco shall not make any
representation contrary to this paragraph.
6.

Effective Date. The “Effective Date” shall be the date that Medco executes the

attached Consent form.
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7.

Effective Date of Section V. Notwithstanding that Medco shall endeavor to comply

with all injunctive terms in Section V as promptly as practicable, Sections A.4, A.5, B, C, D, E, and
F.l, all in Section V above, shall be effective 120 days after the Effective Date.
IX. COMPLIANCE PROVISIONS
1. Within 30 days after the Effective Date of this Order, Medco must provide a copy of this
Order and obtain a signed and dated acknowledgment o f receipt from:
a.

each officer and director;

b.

Medco senior management, namely, the top 200 leadership positions at Medco, which
shall include the Chief Executive Officer, each position that reports to the CEO
(excluding Administrative Assistants), each position that reports to a position that
reports to the CEO (excluding Administrative Assistants), and all other “grade 3"
employee positions under Medco’s current grading system;

c.

each managers of Medco pharmacies, managers of managed care operations, and
pharmacists involved in drug interchange communications with patients or prescribes;
and

d.

each customer service representative to whom a telephone call concerning Drug
Interchanges may be directed in the routine routing of calls.

2.

For five years from the Effective Date, Medco shall provide a copy of this Order and

obtain a signed and dated acknowledgment of receipt from future personnel described in 1 (a) through
(d) of this section within 30 days after the person assumes such position or responsibilities.
3.

Medco shall make this Order accessible to Client Plans and Patients through its

website.
4.

Medco shall maintain an executive review panel to assess, on a quarterly basis,

Medco’s compliance with this Order. As warranted the panel will review and/or recommend
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initiatives to ensure that Medco’s drug interchange practices and disclosures to Prescribers, Patients
and Client Plans comply with this Order.
5.

Medco shall maintain and distribute methods and procedures (M&Ps) establishing a

code of conduct for all Medco employees engaged in the drug interchange program. The M&Ps must
be designed to establish quality standards for the manner in which information is disseminated to
Prescribers and Patients by Medco employees regarding drug interchanges. Medco will review the
M&Ps annually with their pharmacists and other personnel involved with the drag interchange
program.
6.

Medco shall create and retain, for a period of five (5) years following the date of

creation, books and records that in reasonable detail accurately reflect Medco’s compliance with this
Order. These records must include, but are not limited to, the following:
a.

documents reflecting the current addresses, telephone numbers, fax numbers and email
addresses for Medco and its subsidiaries;

b.

the original signed and dated acknowledgements of the receipt of the Order described
in paragraph 1 o f this section;

c.

documents provided to or received from Client Plans concerning any Client Plans’
instructions, if any, concerning opting out of any provisions of this Order;

d.

an exemplar of each written notice sent to Prescribers regarding Drug Interchanges;

e.

an exemplar of each written notice sent to Patients regarding Drug Interchanges;

f.

a copy of each script used in telephonic communications with Prescribers and Patients
relating to Drug Interchanges;

g.

a copy of all training materials used to inform employees of the requirements of this
Order;

h.

a copy of all M&Ps developed by the executive review panel;

i.

the P&T Committee information described in Section V.C.(6);
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j.

documents concerning the drug pairs subject to Drug Interchanges;

k

documents reflecting Patient rejections of Drug Interchanges; and

1.

Exemplars of Medco’s quarterly and annual disclosures to client plans required by
section V E of this order.

7.

One year after the Effective Date, and then annually for five years from the Effective

Date, Medco shall provide to the Attorney General of each Participating State a certification, signed
by a Medco senior officer, certifying Medco’s compliance with this Consent Order. Medco’s annual
certification may be accompanied by a report showing the manner in which Medco has complied with
the Consent Order.
8.

For a period o f five years beginning on the Effective Date of this order, and within

thirty (30) days of a written request by an Attorneys General, Medco shall provide to that Attorneys
General:
a.

Copies of the documents described in the preceding paragraph; and

b.

such other records and documents as the Attorneys General determines reasonably
bear on compliance with this Order.

9.

Nothing in this Order limits the Attorney General’s lawful use of compulsory process

to investigate whether Medco has violated any provision of law enforced by the Attorneys General.
X.
1.

ADMINISTRATIVE PROVISIONS

Jurisdiction is retained of this matter for all purposes, including but not limited to, the

purpose of enabling any of the parties to this Order to apply to the Court at any time for such further
orders or directives as may be necessary or appropriate for the interpretation or modification of this
Order, for the enforcement o f compliance therewith or for the punishment of violations thereof.
2.

The State shall give Medco 30 days’ notice before filing a motion or other pleading

seeking contempt of court or other sanctions for violation of this Consent Order. The giving of such
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notice shall not prevent the State from beginning such proceeding following the expiration of the 30
day period.
3.

Any party to this Consent Order may petition the Court for modification on thirty (30)

days’ notice to all other parties to this Consent Order. Medco may petition for modification if it
believes that the facts and circumstances that led to the State’s action against Medco have changed in
any material respect. The parties by stipulation may agree to a modification of this Consent Order,
which agreement shall be presented to this Court for consideration; provided that the parties may
jointly agree to a modification only by a written instrument signed by or on behalf of both Medco and
the State. If Medco wishes to seek a stipulation for a modification from the State, it shall send a
written request for agreement to such modification to the Attorney General of the state at least 30
days prior to filing a motion with the Court for such modification. Within 30 days of receipt from
Medco of a written request for agreement to modify, the Attorney General of the State shall notify
Medco in writing if the Attorney General of the State agrees to the requested modification.
4.

. If, after the date of entry of this Consent Order, the State, its Attorney General, or any

agency of the State enacts or promulgates legislation, mles or regulations with respect to matters
governed by this Consent Order that conflict with any provision of this Consent Order, or if the
applicable law of the State shall otherwise change so as to conflict with any provision of this Consent
Order, the Attorney General shall not unreasonably withhold its consent to the modification of such
provision to the extent necessary to eliminate such conflict. Laws , rales, or regulations, or other
change in State law, with respect to the matters governed by this Consent Order, shall not been
deemed to conflict with a provision of this Consent Order unless Medco cannot reasonably comply
with both such law, rale, or regulation and an applicable provision of this Consent Order.

Dated:_______________

______________________________
Justice, Superior Court
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CONSENT TO JUDGMENT
1.

Medco acknowledges that it has read the foregoing Consent Order, is aware of its right

to a trial in this matter and has waived that right.
2.

. Medco admits to the jurisdiction of the Court and consents to the entry of this Consent

3.

Medco states that no promise of any kind or nature whatsoever (other than the written

Order.

terms of this Consent Orderjwas made to it to induce it to enter this Consent Order, that it has entered
into this Consent Order voluntarily, and that this Consent Order constitutes the entire agreement
between Medco and the State
4.

David B. Snow, Jr. represents that he is the Chairman, President and Chief Executive

Officer of Medco, formerly Merck-Medco Managed Care L.L.C., and that, as such, he has been
authorized by Medco to enter into this Consent Order for and on behalf of all entities bound by this
Consent Order.

Dated:

f A- ^

V
David B. Snow, Jr
Chairman, President, CEO
Medco Health Solutions, Inc.
100 Parsons Pond Drive
Franklin Lakes, NJ 07417

31

Dated:

T Z ^
«

D l
I

Portland, ME 04112-7320
Tel. (207) 774-9000
S ta te o f Maine Bar # : 336
ATTORNEY FOR DEFENDANTS

Dated:

2.(p | q4
Linda J. Conti
7
Assistant Attorney General
Maine Bar No. 3638
Office of the Attorney General
6 State House Station
Augusta, ME 04333-0006
Tel. (207) 626-8591
ATTORNEY FOR PLAINTIFF
STATE OF MAINE
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CERTIFICATION
I,

David S. Machlowitz, Senior Vice President, General Counsel and Secretary of

Medco Health Solutions, Inc. (the "Company"), a corporation duly organized and existing
under the laws of the State o f Delaware, do hereby certify that the following, presently in
full force and effect, is a true and correct copy of the resolutions adopted by the Board of
Directors of the Company at a Special Meeting on April 12, 2004:
WHEREAS, beginning in or about August 2002, a multi-state task force of
Attorneys General reviewed a number o f the Company’s practices including, inter alia,
therapeutic interchanges and rebates, for violations o f certain state consumer protection
and anti-trust laws; and
WHEREAS, the Company cooperated with such multi-state task force, produced
documents to the multi-state task force, and answered questions raised by the multi-state
task force; and
WHEREAS, after negotiations, the multi-state task force and the Company have
agreed in principal on certain changes to the Company’s business practices and a
monetary settlement;
NOW, THEREFORE, BE IT
RESOLVED, that the form of Consent Order o f Court fo r Permanent Injunction
and Monetary Settlement previously distributed to the Board o f Directors, described at
this meeting hereby is, approved, with such additions, deletions, changes and
clarifications as the officers o f the Company deem appropriate in their reasonable
discretion.
IN WITNESS WHEREOF, I have hereunto subscribed m y signature and affixed
the seal of the Company t h i s ' l l day o f April, 2004.

David S. M achlowitz
s'
Senior Vice President, General
Counsel and Secretary

STATE OF MAINE
KENNEBEC, SS.

SUPERIOR COURT
CIVIL ACTION
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STATE OF MAINE

)
)
)
)

Plaintiff,
-v-

)

MEDCO HEALTH SOLUTIONS, INC.,
MERCK-MEDCO MANAGED CARE, L.L.C.,
Defendants

:

________________ _______ ________________________

CONSENTORDER

)
)
)
)
)

)

Plaintiff, State of Maine, acting by Attorney General G. Steven Rowe, has brought this action
pursuant to the Maine Unfair Trade Practices Act, 5 M.R.S.A. §§ 207 and 209, having filed a
complaint against the Defendants, Medco Health Solutions, Inc. and Merck-Medco Managed Care,
L.L.C., and the parties having consented to the entry of this Consent Order (“Order”) for the purposes
o f settlement only, without this Order constituting evidence against or any admission by any party,
and without trial of any issue of fact or law, NOW THEREFORE, upon the consent of the parties
hereto IT IS HEREBY ORDERED, ADJUDGED AND DECREED AS FOLLOWS:
I. PARTIES
1.

The State of Maine is the plaintiff in this case.

2.

Medco Health Solutions, Inc., and its corporate predecessor, Merck-Medco Managed

Care, L.L.C., together with their subsidiaries and affiliates (hereafter collectively referred to as
“Medco”) are the defendants in this case. Medco has its principal place of business at 100 Parsons
Drive, Franklin Lakes, NJ 07417. Medco is a pharmacy benefits manager, which administers
pharmacy benefits for health plans and employers, including governmental employers.

notice shall not prevent the State from beginning such proceeding following the expiration of the 30
day period.
3.

Any party to this Consent Order may petition the Court for modification on thirty (30)

days’ notice to all other parties to this Consent Order. Medco may petition for modification if it
believes that the facts and circumstances that led to the State’s action against Medco have changed in
any material respect. The parties by stipulation may agree to a modification of this Consent Order,
which agreement shall be presented to this Court for consideration; provided that the parties may
jointly agree to a modification only by a written instrument signed by or on behalf of both Medco and
the State. If Medco wishes to seek a stipulation for a modification from the State, it shall send a
written request for agreement to such modification to the Attorney General of the state at least 30
days prior to filing a motion with the Court for such modification. Within 30 days of receipt from
Medco of a written request for agreement to modify, the Attorney General of the State shall notify
Medco in writing if the Attorney General of the State agrees to the requested modification.
4.

If, after the date of entry of this Consent Order, the State, its Attorney General, or any

agency of the State enacts or promulgates legislation, rules or regulations with respect to matters
governed by this Consent Order that conflict with any provision of this Consent Order, or if the
applicable law of the State shall otherwise change so as to conflict with any provision of this Consent
Order, the Attorney General shall not unreasonably withhold its consent to the modification of such
provision to the extent necessary to eliminate such conflict. Laws , rules, or regulations, or other
change in State law, with respect to the matters governed by this Consent Order, shall not been
deemed to conflict with a provision of this Consent Order unless Medco cannot reasonably comply
w itirboth suciriawTTnie, or regukttcmundrarrnpphcaMe^roviston of tbis-Censcnt Order.----------------
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STATE OF MAINE
KENNEBEC, SS.

SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-04)
)

STATE OF MAINE

)

v.

)

MERCK-MEDCO MANAGED
CARE, L.L.C., and
MEDCO HEALTH SOLUTIONS, INC.

)
)
)
)

CO M PLA IN T

)
Defendants

)

___________________________________________ )

INTRODUCTION
1.

This civil action is brought by Attorney General G. Steven Rowe in the public

interest, arising out o f the defendants’ unfair or deceptive acts and practices in connection with
the sale of, and performance of, pharmacy and pharmacy benefit management services. By this
action, the A ttorney General seeks permanent injunctive relief prohibiting the defendants from
committing unfair and deceptive acts and practices in the future, as well as restitution for persons
injured by the defendants’ unlawful actions, and other remedies provided by 5 M.R.S.A. § 207 of
the Maine Unfair Trade Practices Act (“UTPA”).
THE PARTIES
2.

This action is brought by the Attorney General on behalf o f Maine citizens,

pursuant to 5 M.R.S.A. §§207and 209, and the power vested in him under common law.
3.

Defendant, Medco Health Solutions, Inc. (“Medco”), is a Delaware Limited

Liability Corporation that conducts business nationwide, with pharmacy facilities located in 12
states. It is the corporate successor to the defendant Merck Medco Managed Care, L.L.C.

Medco Health Solutions, Inc. and Merck-Medco Managed Care L.L.C. are collectively referred
to as “Medco”. Medco provides pharmacy benefit management services to persons in Maine and
nationwide.
4.

Medco operates, or has operated, prescription drug mail order pharmacies under

the names o f wholly owned subsidiaries including, but not limited to, Merck-Medco Managed
Care o f California, Inc.; Defendant, Merck-Medco Rx services o f Florida No. 2, L. C. (“Tampa
II”); Defendant, Merck-Medco Rx services o f Florida, L.C. (“Tampa I”); Merck-Medco Rx
services o f Massachusetts, L.L.C.; Defendant, Merck-Medco Rx services o f Nevada, Inc.;
Merck-Medco Rx services of New Jersey, L.L.C.; Merck-Medco Rx services o f New York,
L.L.C.; Merck-Medco Rx services o f Ohio, Ltd.; Merck-Medco Rx services o f Ohio No. 2, Ltd.;
Merck-Medco Rx services o f Oklahoma, L.L.C.; Merck-Medco Rx services o f Pennsylvania,
L.L.C.; Merck-Medco Rx services o f Pennsylvania No. 2, L.L.C.; Defendant, Merck-Medco Rx
services o f Texas, L.L.C.; Merck-Medco Rx services o f Virginia, L.L.C.; and Merck-Medco Rx
services o f Washington, Inc. (collectively “mail order pharmacies”). Each o f Medco’s mail order
pharmacies is licensed as a pharmacy under the laws o f the state in which it is located, and is
licensed by each state to which that mail order pharmacy ships prescriptions. Each o f the mail
order pharmacies is controlled by, and are alter egos of, Medco.
5.

Systemed, L.L.C. also is a wholly owned subsidiary o f Medco. Systemed engaged

in similar or identical pharmacy benefit manager practices as Medco, except with a client focus
on smaller to medium sized businesses. For purposes o f this complaint, Systemed is the alter ego
o f Medco.
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JURISDICTION AND VENUE
6.

This court has jurisdiction over the subject matter and defendants o f this action

pursuant to 5 M.R.S.A. § 209 and 4 M.R.S.A. § 105.
FACTS
I.

M edco’s Pharmacy Benefit Manager Business
7.

Over 150 million Americans have insurance coverage which includes a pharmacy

benefit component that pays for prescription drugs, in whole or in part. W hether provided by an
employer, a health plan, a government agency, a union or another entity (the “client”), this
pharmacy benefit is typically managed by a pharmacy benefit manager (“PBM ”). The PBM is a
business which specializes in administering the pharmacy benefit in return for payment - in some
form - by the client. Medco is a PBM. According to Medco, it is the nation’s largest PBM,
based on 2002 net revenues o f more than $32 billion.
8.

As a PBM, Medco generally performs the following tasks for its clients:
a.

Organizing a network o f retail pharmacies (“retail network”), now
numbering more than 55,000 pharmacies, that agree to fill prescriptions
for a negotiated price.

b.

Operating mail order pharmacies which sell prescription drugs, including
more than 82 million prescriptions in 2002, directly to patients.

c.

Administering the pharmacy benefit by processing and paying claims
through operation o f a proprietary computer system.

d.

Providing patients, physicians, and clients with information about the
operation o f their pharmacy benefit and cards or other methods to access
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the benefits.
e.

Providing expert advice concerning the design o f prescription drug plans
in order to provide a quality program while containing costs to the client
and the patients. Aspects o f a pharmacy benefit plan design include levels
o f co-payment by patients, limits on total amount o f drug spending
covered, use and pricing o f generic drugs, pre-authorization requirements,
and formulary decision making such as when plans should require use o f
older, cheaper drugs before paying for newer, more expensive drugs.

f.

Providing expert advice concerning the development and management o f
formularies, as described further below.

9.

Formularies are lists o f preferred drugs for which a plan agrees to pay on behalf o f

the patient, either in whole or in part. For example, “open formularies” permit payment for any
prescription drug. “Closed formularies” limit payment to specific drug - for example, only
generics, or only one drug within a so-called “therapeutic class.” “Tiered formularies” require
patients to pay lower or higher co-pays depending on whether a drug is generic, preferred brand,
or non-preferred brand.
10.

Medco maintains a Pharmacy & Therapeutics Committee (“P&T Committee”),

composed o f doctors and pharmacists, to make clinical and/or medical determinations about
which drugs to include on Medco formularies.
11.

Medco represents to its clients that its “Preferred Prescription Drug Formulary”

list is reviewed by an independent P&T committee and will allow health plans to achieve quality
care as well as cost containment objectives.
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II.

M edco’s M ail Order Pharmacy Business
12.

At all material times, Medco provided mail order pharmacy services to clients

including state and local governmental clients, as well as Federal employee and retiree groups
and private parties.
13.

Mail order pharmacy benefits were provided through contracts between Medco

and its clients, including State Government Plans, or through sub-contracts entered into by
entities on behalf o f the clients.
14.

Medco, itself and through the mail order pharmacies, is engaged in the practice o f

pharmacy and is licensed to do so under the laws o f various states in which its mail order
pharmacies are located. As a licensed pharmacy, Medco owes certain duties to the patients
whose prescriptions it receives, fills, or arranges to fill. Medco employs licensed professional
pharmacists and licensed, certified, or designated pharmacy technicians who perform or assist in
performing professional pharmacy services for patients.
15.

Medco represents to clients and to patients that it will provide the same

professional pharmacy services performed by professional pharmacists at non-mail order
pharmacies. These services, if properly performed, assure quality o f care for patients through
prevention of adverse drug interactions, verification o f drug strength and dosage regimens,
recommendation o f alternative medically appropriate drugs, and monitoring outcomes.
16.

The mail order pharmacy contracts between Medco and its clients, including State

Government Plans, require that Medco perform professional pharmacy services consistent with
state law requirements, such as drug utilization review (“DUR”) and prescription drug
counseling. Many o f Medco’s client contracts provide that Medco’s compliance with applicable
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state pharmacy law is an express condition for payment for each prescription filled by a Medco
mail order pharmacy.
17.

Client contracts with Medco for mail order pharmacy services also typically

include a number o f quality assurance standards, for example, concerning accuracy rate in filling
prescriptions (e.g., less than one error in 20,000 prescriptions), and concerning standards for
prescription turnaround time (e.g., that prescriptions will be filled within an average o f three days
from receipt o f the prescription).
III.

M edco’s Drug Switching Programs
A.

M edco Offers “Drug Switching” and other Formulary Compliance Programs
Purportedly to Save Clients Money.

18.

The amount o f money spent on prescription drugs by public and private health

plans and employers has risen dramatically in the past decade. One o f the principal benefits
claimed by Medco when it solicits PBM clients is Medco’s ability to save clients money on
prescription drug spending.
19.

Medco represents to existing and prospective clients that several facets o f its PBM

services allow Medco to save money for clients. Medco agrees to provide clients prescription
drugs at a contractual discount (typically a discount off so-called “AWP”, or average wholesale
price), either through its retail pharmacy network or directly through Medco’s mail order
pharmacies. Medco also promises to save money by generating manufacturer rebates and by
engaging in “formulary compliance” programs, like drug switching, as alleged further below.
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1.

20.

Medco Offers Drug Switching Programs to Generate Rebates from Drug
Manufacturers, In Order to Save Clients Money.

In addition to agreeing to provide clients prescription drugs at a percentage

discount, Medco also represents that it will save clients money by negotiating and obtaining
“rebates” from drug manufacturers. Medco represents that its ability to earn such rebates from
drag manufacturers, and thereby save clients money, is tied to the formulary established by
Medco and to Medco’s formulary compliance efforts, including its ability to switch patients from
one brand-name drug to another.
21.

Specifically, Medco represents to clients and prospective clients that if the client

agrees to use Medco’s formulary management services, Medco will generate rebates tied to
Medco’s formulary and to switching programs, and thereby save money. In its typical contract
with clients, Medco states that it will: i) receive “Formulary Rebates” as a result o f including
branded products on Medco’s formulary; as well as ii) conduct “therapeutic interchange
programs” (i.e., switch programs) for formulary drags, which lead to cost savings. In its
solicitation o f clients and in its contracts with clients, Medco represents that formulary and
switching-based rebates and savings are integral to Medco’s ability to save clients money. In
light o f Medco’s cost-savings claims, many Medco clients, including state governmental clients,
participate in Medco’s formulary management programs, such as Medco’s Preferred Prescription
Formulary and its switching programs.
22.

Critical to Medco’s representation that it will save clients money by obtaining

formulary- and switching-based rebates from drag manufacturers is Medco’s claim that it will
“pass through” to clients those rebates. Medco’s agreement to pass rebates through to its clients
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is essential because, absent that promise, rebates generated by Medco’s formulary management
or switching programs would not necessarily result in rebates and savings to the plan, which
Medco claims are the reason its switching and other formulary compliance measures.
23.

In Medco’s solicitation o f clients, promotional materials, contracts with clients,

communications with clients, and communications with patients and others carrying out its
switch programs, Medco purposely generates the overall impression that the purpose and effect
o f its drug switching programs is to save client plans money on prescription drugs.
2.

24.

Medco’s Formulary Decisions and Switch Programs Often are Driven
by its Agreements to Receive Money from Drug Manufacturers.

Medco’s formulary decisions and drug switching programs - i.e., determinations

o f which drugs will be preferred on the formulary and which drugs will be targeted for brand-tobrand drug switches - turn to a large degree on Medco’s contracts with drug manufacturers. In
its capacity as mail order pharmacy, Medco contracts with these manufacturers to purchase
prescription drugs for mail order dispensing. Medco’s contracts with manufacturers typically
contain a variety o f incentives for Medco and potential payments to Medco based on Medco’s
conduct. Because Medco strikes contracts with substantially all drug manufacturers, its
incentives for selling various drugs are numerous and complex.
25.

By way o f example, many drug manufacturers pay Medco “base” or “formulary”

rebates, typically calculated by applying a flat percentage to Medco’s purchases o f that
manufacturer’s drugs. But the same manufacturer contract may contain other flat percentage
rebates identified by different names (for example, “cost-effectiveness” rebates), and also may
contain more targeted rebates that are tied to specific sales or performance goals (for example,
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“market share” rebates, where percentage rebate increases on a sliding scale as market share
increases).
26.

In sum, Medco receives dozens o f types o f rebates from manufacturers. Some

rebates, namely “base” and “formulary” rebates, are classified as “formulary” and thus passed
through to clients who receive a portion o f formulary rebates. Many other rebates are not
classified as “formulary” rebates by Medco, and Medco therefore retains those rebates. Until
very recently, Medco typically did not disclose to its clients the magnitude o f non-formulary
rebates that were retained by Medco. On information and belief, the vast majority o f Medco
clients never learned the magnitude o f Medco retained rebates. From 1997 through 2002, the
total of Medco-retained rebates were roughly equal in magnitude to the total o f formulary
rebates, which typically were disclosed and passed through to Medco clients (in accordance with
contracts).

3.
27.

Medco ’s Managed Care Pharmacists Carry Out Medco’s Drug Switches.

Medco’s mail order drug switching programs are carried out by pharmacists and

other personnel in the Managed Care departments at Medco’s mail order pharmacies. Medco
provides training, instruction, phone scripts and other form communications to all Managed Care
personnel concerning how to solicit drug switches from prescribing doctors.
28.

Medco’s Managed Care Departments' principal purpose is to switch patients’

prescriptions from a currently prescribed drug to a target drug. These drug switches sometimes
reduce costs to clients, but always promote Medco’s financial interests, sometimes without
sufficient regard to the switch’s negative impacts on client plans or patients, as alleged below.
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B.

Medco Conducted Drug Switches That Benefited Medco but Did Not Save
Clients Money, or Did Not Save Enough Money to Justify the Intervention.

29.

Notwithstanding Medco’s representations that its switch programs are designed to

save clients money and will save clients money, Medco engaged in certain drug switches that
failed to advance the purpose promoted by Medco - saving clients and patients money.
30.

On information and belief, Medco carried out switch programs that may not have

saved money because the proposed switches either favored target drugs that were more expensive
than drugs originally prescribed, or had the effect o f favoring drugs without a generic equivalent
over drugs with a generic equivalent.
31.

Medco has engaged in drug switches and made formulary decisions that generated

revenue for Medco but failed to generate cost savings or other benefits for Medco’s clients.
Medco solicited and obtained agreements with drug manufacturers by which the manufacturer
would pay Medco for drug switches, formulary preferences or formulary compliance measures
favoring the manufacturer’s products, but where the manufacturer’s payments to Medco would
not be “passed through” to Medco’s clients. When Medco, pursuant to such agreements, carried
out switches and formulary decisions to generate revenue for itself without passing through
revenue to its clients, Medco’s switch programs and formulary decisions were driven by Medco’s
conflicted interest, not by cost savings for the client.
32.

Medco also engaged in switch programs and formulary decisions that favored

Medco’s former parent company, Merck, but failed to achieve costs savings to Medco’s clients.
33.

Each o f these types o f switch initiatives increased, rather than decreased,

prescription drug spending by Medco’s clients, while enriching Medco. In light o f this conduct,
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Medco, when it solicited clients and solicited client participation in Medco’s switching and
formulary initiatives, failed to disclose material information concerning its switching and
formulary programs.
C.

Medco Conducted Drug Switches that Did Not Save Clients Money Because
The Switches Shift Switch-Related Costs to Client Plans and Patients.

34.

Notwithstanding Medco’s representations that its switch programs are designed

to, and do save clients money, Medco has engaged in certain drug switches that, on information
and belief, increased, rather than decreased, total health care costs to Medco’s client plans and to
patients.
1.

35.

Medco Drug Switches Required Clients and Patients to Pay Costs
Attributable to the Switch.

Medco conducted switches that increased overall costs even though they may have

involved a nominally lower priced target drug. These drug switches sometimes raised health care
costs to client plans and patients, contrary to Medco’s representations, by shifting switch-related
costs from Medco to its client health plans and patients.
36.

With respect to certain drug therapies, a switch from one drug to another in the

same therapeutic class often requires one or more tests, and may require one or more doctor
visits, to monitor the new drug therapy and ensure the new drug’s efficacy. These additional
health care costs often would not have been incurred but for Medco’s proposed drug switches.
37.

By way o f example, Medco engaged in several switch programs involving statin

drugs, including Mevacor and Zocor (manufactured by Merck), Lipitor (Pfizer), Pravachol
(Bristol-Myers Squibb) and Baycol (Bayer). Statins are cholesterol lowering agents prescribed to
millions o f Americans to lower cholesterol levels and to help avoid heart disease.
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38.

These various statin products are in the same therapeutic class but are not

identical. To responsibly change a patient from one statin to another, the prescribing doctor often
requires the patient to undergo a fasting lipid/ cholesterol test after commencing the new drug
therapy. After analyzing the test results, the doctor should confirm the efficacy o f the dosage or
adjust it as necessary. The statin drug switch change thus may require the patient, and his or her
health plan, to incur costs associated with lab tests and/or doctor visits.
39.

In addition to statins, Medco conducted drug switch programs involving other

therapeutic classes that ultimately caused patients and health plans to incur costs related to tests
or doctor visits attributable to the drug switch.
40.

Such tests and doctor visits, resulting from Medco’s drug switch program, cost

money. Medco did not pay for these switch-related costs; the vast majority were borne instead
by both clients and patients. Costs to the patient included applicable co-payments for testing
and/or doctor visits for dosage adjustment. The client paid the balance o f the costs o f testing and
doctor visits.
41.

On information and belief, with respect to certain o f Medco’s drug switches, the

switch-related costs borne by the client plans and patients exceeded costs savings attributable to a
lower price for the new drug. In those circumstances, certain o f Medco’s drug switches
increased, rather than decreased, overall costs to Medco’s client plans and patients.

2.

42.

Medco Failed to Adequately Disclose, and Failed to Comply with, Its
Policy To Cover Statin Switch-Related Costs.

With respect to at least statin drug switches, Medco represented that it has a policy

to address switch-related costs. In communications with doctors soliciting a statin switch,

12

Medco claimed that it would pay additional costs incurred due to a Medco-proposed drug switch.
In practice, Medco fails to meaningfully follow its nominal policy to cover switch-related costs
for statin switches, instead making it difficult for doctors, plans or patients to obtain
reimbursement.
43.

When Medco undertakes certain switch programs, such as statin switches, Medco

knows that its proposed switch will result in tests and/or doctor visits for which the health plan
and patient will be charged money. Nonetheless, when Medco personnel, following Medco
scripts or forms, initially solicit switches from doctors, Medco makes no mention o f switchrelated costs. Likewise, when Medco notifies the patient o f a drug switch, it makes no mention
o f switch-related costs nor Medco’s policy to cover those costs. Medco instructs its Managed
Care pharmacists to not discuss switch-related costs unless a doctor or patient affirmatively
demands to have costs covered. Medco’s actual practice with respect to statin switch-related
costs is designed to undermine its nominal policy to cover those costs, and has the desired effect.
44.

Even when a doctor or patient objects to switch-related costs, Medco purposely

makes it difficult for either party to obtain the benefit o f Medco’s nominal policy. Medco
pharmacists refer doctors to a separate toll free number in order to process a costs request, even
though Medco could automatically process such a doctor request. As a result o f Medco’s
practices, a small percentage o f switch-related costs are actually paid by Medco, even in the
statin therapeutic class.
45.

Even when Medco agrees to reimburse a patient’s switch-related costs, that

reimbursement is limited to the co-pay incurred by the patient and does not include costs paid by
the patient’s health plan, Medco’s client.
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46.

On information and belief, Medco knew that certain drug switches would require

plans and patients to incur switch-related costs that would offset savings nominally attributable
to certain drug switches. Medco also knew that, if Medco itself covered these switch-related
costs consistent with its purported policy, these switches overall would not generate revenue for
Medco. Medco nonetheless engaged in these switches so long as they were profitable for Medco,
shifting costs to Medco’s client plans and patients so as to increase, not decrease, overall costs to
the plan and patients.
47.

In its communications with clients and patients, Medco fails to disclose its actual

practices with respect to switch-related costs and fails to disclose that the vast majority o f switchrelated costs are covered by plans and patients, not Medco.
3.

48.

Other Switching Costs Are Incurred by Physicians and the Health Care
System Generally.

In addition to Medco shifting switch-related costs to its client plans and patients,

Medco’s switching programs shift considerable costs to doctors and the health care system
generally. As Medco is aware from written complaints from physicians, Medco’s drug switch
solicitations demand countless hours from physicians and their staff.
49.

To responsibly evaluate most o f Medco ’s drug switch proposals, a physician

should: a) review Medco’s proposed switch; b) evaluate the patient’s history (which typically
requires staff to access the patient’s file); c) evaluate whether the proposed drug therapy is
clinically suitable for the patient; d) evaluate whether side effects or drug interactions counsel
against the switch; and e) depending on the evaluation, respond to Medco by phone or facsimile.
Many physicians have received multiple switch solicitations from Medco daily, and many
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50.

Such an expenditure o f health care resources could conceivably be justified where

M edco’s switch solicitations meaningfully decrease costs to plans and patients. But to the extent
M edco’s drug switches are motivated by Medco’s own profit as much as reducing costs, the
burden on physicians constitutes another form o f inappropriate cost-shifting from Medco to
others, in order to unfairly enrich Medco.
D.

M edco’s Drug Switch Solicitations Failed to Provide Full and Accurate
Information to Doctors and Patients.

51.

Medco requires its pharmacists to follow drug switching scripts prepared by

Medco, which in some ways limits the information made available to pharmacists and
prescribing doctors related to drug switches.
52.

Medco’s Managed Care pharmacists and other employees at Medco’s mail order

facilities typically solicit drug switches using the following process: A pharmacist or assistant
telephones the prescribing physician to propose a switch for one o f the doctor’s patients. This
phone call is sometimes preceded by a facsimile to the doctor’s office proposing the switch.
Once the Medco pharmacist contacts the prescribing physician or the physician’s staff (several
calls may be required), the pharmacist solicits physician approval for the drug switch using
M edco’s script. A doctor also may authorize a switch by completing and returning Medco’s
facsimile switch request.
53.

If a switch is authorized by the prescribing doctor, Medco generates and sends a

letter to the prescribing doctor confirming the drug switch. Medco also sends a letter to the
patient stating that a switch has been authorized. The patient letter either accompanies the new,
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switched drug prescription (for mail order prescriptions), or asks the patient to make the switch
when his or her prescription is next filled (for prescriptions filled at retail).
54.

In several steps this switch solicitation process, Medco makes misleading

statements to promote switches or fails to disclose material facts related to switches, as alleged
below.
1.

Medco’s Switch Solicitations to Physicians.

55.

Medco’s solicitation o f drug switches from doctors is misleading because:

a)

Medco represents that it is calling on behalf o f the patient’s health plan but fails to
disclose Medco’s own financial incentive for the switch.

b)

Medco generates the misleading impression that the patient’s health plan has
initiated the switch request or that Medco is calling at the plan’s direction, without
disclosing that Medco itself determines when to engage in switch programs.

c)

Some Medco personnel, in order to promote a drug switch, create the false
impression that the proposed switch is required by the patient’s health plan, and
that the currently prescribed drug will not be covered by the patient’s plan.

d)

Medco represents that the proposed switch will save the patient and/or the
patient’s plan money and that Medco’s motivation behind the proposed switch is
cost containment. These representations are false or misleading with respect to
certain switches if: i) the target drug does not cost less, ii) the switch may benefit
Medco but not the plan; and/or iii) switch-related costs incurred by the plan and
patients offset any nominal price savings.
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56.

Medco’s cost containment claims are also misleading because Medco refuses to

disclose to doctors, patients, or even its own pharmacists, any actual pricing information
concerning currently prescribed and target drugs. Medco’s scripts and instructions to its
Managed Care personnel do not include information on the price o f current and target drugs.
Thus, when Medco Managed Care pharmacists initiate drug switches, they have no hard
information to support cost savings - supposedly the very basis for their solicitation.
57.

Medco’s form letters to doctors confirming a switch typically restate many o f the

misleading aspects o f Medco’s initial switch solicitation to doctors. These confirming letters fail
to disclose Medco’s role in the switch, Medco’s financial incentives, and material information
concerning whether the switch will actually save money for plans and patients.
2.
58.

Medco Communications with Patients.

Medco’s form letters to patients confirming a drug switch also fail to disclose

material information, in order to limit the likelihood that patients will object to or seek to reverse
the drug switch. Medco tells patients that their doctor initiated the drug switch or “has
determined” to switch drugs therapies, failing to disclose that the switch was solicited by Medco.
Medco’s letters to patients also state that the switch will save money for the patient’s plan, but
fail to disclose Medco’s financial incentives and other material information (set forth above)
concerning whether the switch will actually save money for plans and patients.
3.

59.

Medco Switched Drugs without Doctor Authorization.

On occasion, Medco also switched prescription drugs without obtaining

authorization from the prescribing doctor. Medco personnel either claimed they had obtained
physician authority when they had not, or accepted switch authorization from a member o f a
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IV.

M edco’s Drug Switching Programs Implicate State Pharmacy Law and Pharmacist
Ethical Standards.
60.

Medco and its pharmacists are engaged in the “practice o f pharmacy” under State

law 32 M.R.S.A. § 13702(22). A non-exclusive list o f activities that qualify as being part o f the
“practice o f pharmacy” under state laws include: interpreting prescription orders; dispensing and
labeling o f drugs; monitoring o f drug therapy and use; conducting drug utilization reviews;
participating in drug product selection; maintaining records; and providing information on legend
drugs.
61.

Pharmacy ethics require honesty, integrity, and professionalism at all times.

Central to pharmacy ethics is recognition that the relationship between patient and pharmacist is
a covenant based on trust and that the well-being o f the patient is primary. All engaged in the
practice o f pharmacy must be dedicated to the best interests o f the patient. Pharmacy ethics
include the duty to provide unbiased information and the duty not to provide information made
biased by pecuniary interests. Business practices and work conditions that undermine that
dedication or that impair a pharmacist’s professional judgment are unethical.
62.

Because o f the potential for improper conflicts o f interest, and even where neither

the patient nor the plan would be harmed by the switch, pharmacy ethics require full disclosure
o f all material facts, including cost rationality and transparency, relating to drug switching in
order for patients and doctors to make fully informed decisions. When a physician or consumer
asks Medco about the cost or price o f a medicine, Medco and its pharmacists are obligated to
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provide that information with respect to both the drug’s cost to the plan and the patient’s co-pay.
63.

Pharmacy ethics also demand that Medco and its pharmacists monitor the

effectiveness and the effects o f the drug switches proposed by Medco. Medco has an obligation
to monitor the drug switches it proposes, both generally and as to the specific patients involved.
In addition, before proposing a drug switch, Medco pharmacists are ethically obligated to form
an independent professional judgment that a proposed switch would be in the patient’s best
interest and appropriate.
64.

Drag switches, to be ethically proposed, much also be cost-effective from an

overall health-care standpoint. Thus, drag switches that shift cost-burdens to others, such as
health plans and patients, so as to effectively increase overall health care costs, are improper and
unethical.
65.

Medco has committed unfair or deceptive acts or practices through its violation o f

pharmacy ethics in at least the following ways:
a)

By failing to fully disclose to patients, plans, and physicians all o f the material
facts supporting proposed drag switches, including the nature and amount of
Medco’s financial interest, and savings to the patient and the plan, if any;

b)

By failing to monitor and track its drag switches from a health and safety
standpoint, both individually and generally;

c)

By failing to require that its pharmacists form an independent professional
judgment about the propriety o f a drag switch before proposing it, and by
promoting protocols and work conditions that operate counter to this obligation;

d)

By failing to ensure that proposed drag switches are rational, not just from a cost-
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of-drug perspective, but from an overall heath-care cost perspective, especially
where additional doctor’s visits or lab tests should be anticipated;
e)

By failing to disclose adequately and pay for additional health care costs resulting
from drug switches proposed by Medco for its own economic benefit; and

i)

By failing to provide cost and price information when requested by either the
patient or the physician.
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CAUSES OF ACTION

COUNT ONE
Unfair or Deceptive Acts or Practices
in Violation of the Unfair Trade Practices Act
66.

The allegations contained in paragraphs 1 - 65 are incorporated herein by

reference.
67.

The defendants, Medco Health Solutions, Inc. and Merck-Medco Managed Care

L.L.C. (“Medco”) have violated 5 M.R.S.A. § 207 by engaging in various unfair and deceptive
acts or practices, including but not limited to the following:
a)

Although Medco represented that the purpose and effect o f Medco’s drug
switching programs were to save money for its client plans and patients, Medco
engaged in drug switching programs that increased, rather than decreased, costs to
plans and patients, including by:
i) advocating drug switches that required follow-up patient testing and doctor
visits, which caused client plans and patients to pay switch-related costs for
testing and doctor visits;
ii) advocating drug switches where the switch-related costs borne by client plans
and patients exceeded cost savings attributable to the drug switch;
iii) advocating drug switches to higher priced drugs.

b)

Medco failed to adequately follow its policy for paying statin switch-related costs
like testing and doctor visits.

c)

In soliciting and obtaining drug switches, Medco sometimes made misleading
statements to doctors and patients, and failed to disclose material information
concerning the proposed drug switches, including:
i) failing to disclose material facts concerning cost containment, that the target
drug may be more expensive, M edco’s financial interest in the switch, and switchrelated costs likely to result from the switch.
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ii) failing to disclose to doctors and patients actual pricing information with
respect to the currently prescribed and target drugs.
iii) misrepresenting to doctors that Medco was calling on behalf o f the patient’s
health plan, without disclosing Medco’s own incentives for the switch solicitation;
iv) misrepresenting to patients that a drug switch was initiated by the patient’s
doctor, and failing to disclose that Medco initiated the drug switch.
d)

Medco switched prescription drugs without first obtaining authorization from the
prescribing physician, and solicited and accepted purported authorization from
persons whom Medco knew, or should have known, were not authorized to
approve a drug switch.

e)

Medco carried out switch programs but failed to adequately monitor the potential
for side effects and other negative health consequences;

f)

Medco’s switching practices sometimes encouraged pharmacist conduct contrary
to pharmacy ethical rules.
RELIEF REQUESTED

WHEREFORE, the State requests that this court:
1.

Issue a permanent injunction prohibiting the defendants, Merck-Medco Managed

Care, L.L.P. and Medco Health Solutions, Inc., their agents, employees, and all other persons and
entities, corporate or otherwise, in active concert or participation with any o f them, from
engaging in unfair or deceptive conduct.
2.

Order the defendants to make full and complete restitution to each person injured

by their unfair or deceptive acts or practices.
3.

Order the defendants to pay the State o f Maine civil penalties, attorneys’ fees and

costs pursuant to 5 M.R.S.A. § 209.
4.

Grant such other and further relief as the Court deems equitable and proper.

22
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